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Abstract 
Mechanistic Insights into the Roles of IL-22/IL-22RA1 Axis in Oral Antifungal Immunity 
 
Felix Enam Yao Aggor, PhD 
 
University of Pittsburgh, 2020 
 
 
 
 
Oropharyngeal candidiasis (OPC, oral thrush) is an opportunistic infection caused by the 
commensal fungus Candida albicans. IL-17 and IL-22 are produced by Type 17 lymphocytes. 
Both cytokines mediate antifungal immunity yet activate quite distinct downstream signaling 
pathways. While much is now understood about how IL-17 promotes immunity in OPC, the 
activities of IL-22 are far less well delineated. In this dissertation, I focused on identifying 
mechanisms by which IL-22 mediates oral antifungal immunity. In chapters 3 and 4, I identified 
key differences between IL-22 and IL-17-dependent antifungal events during innate OPC 
response. We show that, despite having similar requirements for induction from Type 17 cells, IL-
22 and IL-17 function non-redundantly during OPC. We find that the IL-22 and IL-17 receptors 
are required in anatomically distinct locations within the oral mucosa; loss of IL-22RA1 or STAT3 
in the oral basal epithelial layer (BEL) causes susceptibility to OPC, whereas IL-17RA is needed 
in the suprabasal epithelial layer (SEL). Transcriptional profiling of the tongue linked IL-
22/STAT3 to oral epithelial cell proliferation and survival, but also, unexpectedly, to driving an 
IL-17-specific gene signature. We show that IL-22 mediates regenerative signals on the BEL that 
replenish the IL-17RA-expressing SEL, thereby restoring the ability of the oral epithelium to 
respond to IL-17 and thus to mediate antifungal events. Consequently, IL-22 signaling in BEL 
‘licenses’ IL-17 signaling in the oral mucosa, revealing spatially distinct yet cooperative activities 
of IL-22 and IL-17 in oral candidiasis. In chapter 5, I assessed the roles of IL-22 in T cell recall 
OPC settings. IL-22 is protective in the adaptive response against OPC although the contribution 
 v 
of innate IL-22-mediated responses could not be ruled out. While IL-22 deficiency resulted in 
cervical lymph node (cLN) hypertrophy, there was no evidence of C. albicans translocation to the 
cLN or increased proliferative expansion of Th17 cells. Loss of IL-22 resulted in increased Th17 
(CD4+IL-17A+) but decreased Th1(CD4+IFN-+) frequency. Hence IL-22 may be acting on the 
cLN stroma to modulate T cell responses in recall OPC settings. Our findings have implications 
for antifungal vaccine design strategies and oral immunosurveillance mechanisms against oral 
pathologies and extra-oral diseases. 
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1.0 Introduction 
1.1 Candida and Candidiasis 
Fungal infections are on the rise and remain a serious threat to public health. Yet, to date, 
there are no licensed antifungal vaccines. Among human pathogenic fungi, Candida species 
constitute the major cause of disease. Of the major Candida species, (namely, Candida tropicalis, 
Candida glabrata, Candida parapsilosis, Candida krusei and Candida aureus), Candida albicans 
is the most prevalent cause of infections [1, 2].  
Candidiasis manifests mainly as mucocutaneous or invasive/disseminated disease. 
Mucocutaneous candidiasis includes superficial infections of the skin, nails, vaginal tract and oral 
cavity. Candidiasis of the oral cavity [also known as oral thrush or oropharyngeal candidiasis 
(OPC)] remains the most common human fungal infection [1-3]. C. albicans is a dimorphic fungus 
which exists as a commensal organism on healthy host mucosal surfaces such as the skin and 
mouth with about 50-80% carriage. However, perturbations in oral immunity as observed in 
immunosuppression associated with transplant recipients, radiotherapy and chemotherapy in head 
and neck cancer patients and steroid use in asthma patients can promote its incidence. Additionally, 
denture use, collateral damage from the use of biologics against protective cytokines, decreased 
CD4 count in HIV/AIDS and some congenital immunodeficiency syndromes are risk factors 
associated with oral thrush. During these perturbations, C. albicans transitions into its virulent 
hyphal state to cause disease [4, 5]. Mucocutaneous candidiasis can also develop as persistent or 
recurrent superficial infections of the skin, nails and mucosal membranes [6]. Vulvovaginal 
candidiasis (VVC) presents as burning or itchy sensations of the female genitalia often 
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accompanied by white vaginal discharge. As many as 75% of females may have at least one 
episode of VVC during their lifetime, while another 5% may experience recurrent or chronic 
episodes of vaginal irritation [7, 8]. Other patients experience invasive or disseminated candidiasis 
(generally referred to as candidemia) which may occur when Candida breaches the host epithelia 
and gains access to the blood stream. Candidemia may also occur after surgical procedures due to 
carriage on surgical tools. Candidemia is the second most common nosocomial infection and 
accounts for about 40% mortality [9]. These statistics reveal the enormous burden of Candida on 
human health. 
1.2 Host C. albicans interactions and immunity 
1.2.1 Candida virulence factors 
The morphological plasticity of C. albicans to switch from yeast to hyphae is a key 
determinant of virulence and driver of the host immune response. In the presence of competent 
host immune responses, C. albicans yeast colonize mucosal surfaces without causing overt disease. 
In the absence of effective host immunosurveillance and increased fungal load, C. albicans 
produces hyphal filaments that invade host tissue to cause disease. Consequently, mutant strains 
of C. albicans that fail to form hyphal filaments are non-invasive and avirulent [10, 11]. Hyphae 
formation is therefore a key C. albicans virulence trait. Hyphae formation is characterized by the 
expression of hypha-associated virulence factors [such as hyphal wall protein 1(Hwp1p), secreted 
aspartyl protease (Sap) family proteins, agglutinin-like sequence 3 protein (Als3p), extent of cell 
 3 
elongation 1 protein (Ece1p) and hyphal regulated 1 protein (Hyr1p)], which are important for 
hyphae adhesion, invasion and damage of host cells.  
In the initial stages of infection, C. albicans expresses specific protein adhesins to promote 
attachment to epithelial surfaces. The best characterized C. albicans adhesins belong to the 
agglutinin-like sequence (Als) protein family which consist of 8 members (Als1p-Als7p and 
Als9p). While C. albicans strains lacking Als1p, Als2p, Als3p and Als4p failed to adhere to 
epithelial cells [12-14], Als5-, Als6- and Als7-deficient strains showed enhanced adhesion to 
epithelial cells [15]. The expression of these adhesins therefore appears to have opposing 
consequences and may either favor colonization or invasion of host cells. Hyphal wall protein 1 
(Hwp1p) is important for C. albicans adherence as Hwp1 deficient Candida failed to cause OPC 
in mice [16-18]. Once Candida is strongly attached, it begins to invade host epithelial cells.  
Epithelial invasion is achieved through induced endocytosis or active penetration [19]. 
During endocytosis, C. albicans proteins Als3p and Ssa1p engage epithelial E-cadherin, epithelial 
growth factor receptor (EGFR) and human EGF receptor 2 (HER2) to activate the clathrin 
dependent endocytosis machinery [20-23]. Epithelial aryl hydrocarbon receptor (AhR) also 
mediates C. albicans endocytosis through EGFR activation [24]. Unlike fungal endocytosis which 
is driven by the host, active penetration is dictated by hyphae which must penetrate epithelial cells 
and or circumvent through intraepithelial junctions to breach the mucosal barrier [25, 26]. 
Although the exact mechanism of active penetration is not delineated, hyphal extension, physical 
force exerted by extending hyphae and the secretion of hydrolytic enzymes such as secreted 
aspartyl proteinases (Saps), phospholipases and lipases tend to facilitate the process [19, 27]. 
While Saps are known to promote degradation of host glycoproteins including mucins and E-
cadherins [27, 28], their functional relevance in active hyphal penetration remains controversial, 
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since Sap1-6 failed to play critical roles in C. albicans invasion [29, 30]. Similarly, C. albicans 
phospholipase PLB1 degrades phospholipids present in host epithelial cell plasma membranes to 
facilitate penetration. However, the role of PLB1 remains controversial because PLB1 deficient C. 
albicans did not lose the ability to invade host epithelial cells [25, 31]. Like the phospholipases, 
C. albicans lipases encoded by LIP1-10 gene family are implicated in fungal invasion [32]. 
However, their functional relevance remains uncertain, as multiple groups have reported opposing 
effects of impaired lipase activity or deficiency on C. albicans invasion [25, 33]. 
In the context of OPC, successful C. albicans invasion is accompanied by destruction and 
sloughing of the superficial oral epithelium by secreted fungal factors that induce damage to the 
oral epithelium [27]. The C. albicans gene ECE1 has emerged as a major damage-inducing factor 
during mucosal Candida infection [34]. While ECE1-deficient C. albicans are able to form 
hyphae, adhere to and invade epithelial cells, they fail to damage host epithelium [34]. ECE1 
encodes a 271 amino acid protein (Ece1p) that is cleaved by the endoproteinase Kex2p to generate 
eight distinct peptides [35]. The fragment spanning Ece1p62-93 is further processed by the 
carboxypeptidase Kex1p through terminal Arginine removal to generate the mature peptide, 
known as Candidalysin (Ece1p62-92). Candidalysin is a cytolytic peptide secreted by C. albicans 
hyphae during mucosal invasion and it is thought to signal through the epidermal growth factor 
receptor (EGFR) [36]. Similar to ECE1 mutant strains, candidalysin-deficient C. albicans failed 
to cause epithelial damage and pro-inflammatory responses during mucosal invasion [34]. Both 
strains were also impaired in the ability to induce IL-17A from host lymphocytes [37]. 
Candidalysin has therefore emerged as a critical virulence factor important for C. albicans 
pathogenesis and immune activation at mucosal surfaces.  
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1.2.2 Recognition of C. albicans 
Recognition of invading microbes is achieved through host pattern recognition receptors 
(PRRs) which interact with conserved microbe specific pathogen associated molecular patterns 
(PAMPS) or danger associated molecular patterns (DAMPs) released from infected or damaged 
cells and tissues [38]. The C. albicans cell wall serves as a rich source of PAMPs for PRRs. The 
masked inner skeleton is mainly composed of -(1,3)-glucan and chitin moieties, which are 
anchored to cell wall proteins (mannoproteins) and mannans in the outer layer (Fig.1.1). 
Alterations in the expression and or localization of these cell wall components during yeast to 
hyphal transitions prompt the immune system to distinguish between the commensal yeast and 
pathogenic hyphal forms.  
 
 
Figure 1.1: Structure of C. albicans cell wall 
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The major cell wall components of C. albicans cell wall are shown. Chitin and -(1,3) glucan are 
buried deeper and closer to the outer cell membrane. Cell wall proteins connect -(1,3) glucan 
residues to -(1,6) glucan and mannan residues. 
Invading hyphae lyse host epithelial cells, which then release DAMPs (IL-1  IL-
1 S100A8/9) that promote the expansion of ‘natural’ Th17 (nTh17) cells [37]. In addition, direct 
engagement of PAMPs through PRRs trigger the secretion of cytokines including IL-1, IL-23 
and IL-6. These cytokines promote DC maturation and antigen presentation and polarize naïve 
CD4 T cells into Th17 cells (Fig. 1.2) [38-40]. Toll like receptors (TLR), C-type lectin receptors 
(CLR), and nucleotide binding domain leucine-rich receptors (NLRs) are the main families of 
PRRs implicated in antifungal immunity. While the respective Candida-derived PAMPs necessary 
for fungal recognition by TLRs and CLRs have been defined, PAMPs for NLRs have not been 
definitively identified (Summarized in Table 1.1).  
Among the TLRs, TLR2 and TLR4 are the major PRRs in anti- Candida immunity. There 
are mixed reports on the role of TLR2 in antifungal immunity. While TLR2 ligation promotes 
protective proinflammatory responses in some settings [41-44], TLR2 tends to promote 
immunosuppression and Candida dissemination in other settings [45]. TLR4, on the other hand, 
is protective against disseminated candidiasis [46], and there is no clear requirement for TLR1, 
TLR6 and TLR9 in anti-Candida immunity [39, 47]. In line with the role of TLRs and IL-1R 
signaling in antifungal immunity, mice lacking Myd88 (a central adaptor downstream of TLR and 
IL-1R signaling) are susceptible to Candida infection. Like IL-1, IL-36, another member of the 
IL-1 family of cytokines requires Myd88 to mediate antifungal immunity [48]. However, 
mutations of MyD88 in humans are not associated with fungal infections and may instead suggest 
a more prominent role for other fungal recognition pathways.  
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The CLRs (dectin 1, dectin 2, mincle and mannose receptor) (Table 1.1, Fig. 1.2) and their 
downstream adaptors (CARD9/Bcl-10/MALT1) are implicated in anti-Candida immunity in both 
mice and humans [49-52]. Importantly, while Card-/- mice are susceptible to OPC in adaptive 
settings with impaired IL-17 induction, Card-/- mice are resistant to OPC in innate settings [53]. 
Hence other factors including candidalysin and IL-23 may be more critical than CLRs in fungal 
recognition during acute C. albicans exposure.  
The intracellular inflammasome (mainly composed of NLRP1, NLRP3, NLRP10 and 
NLRC4, their adaptors, and proteases) also contributes to antifungal immunity by recognizing yet-
to-be identified fungal PAMPS. Activation of the inflammasome promotes caspase-1-dependent 
cleavage and secretion of IL-1 and IL-18. While IL-1 promotes Th17 differentiation, IL-18 
polarizes naïve CD4 T cells into Th1 cells [54, 55]. Consequently, NLRP3-/-, NLRP10-/-, NLRC4-/-
, Il1r-/- and ASC-/- are all sensitive to Candida infection and are associated with impaired IL-17 and 
IFN- production [41, 55-57]. 
Although most of these studies focused mainly on PAMP recognition through PRRs on 
APCs, emerging evidence supports a role of epithelial PRRs as well. -glucans have been found 
to activate the epithelial receptor tyrosine kinase Ephrin A2 (EphA2) to induce proinflammatory 
antifungal responses [58]. Regardless of the cell types, efficient recognition of Candida and 
subsequent priming of protective Th17 responses may be dependent on the collective ability of 
PRRs to engage different fungal cell wall components to elicit appropriate stimuli to balance the 
onset and resolution of inflammation. 
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Figure 1.2: Activation of oral mucosal type 17 response to C. albicans 
(A) Phagocytes recognize C. albicans via PRRs (Dectin1/2) leading to the production of Th17 
polarizing cytokines. These cytokines activate STAT3 in type 17 cells to upregulate RORT 
leading to the production of IL-17A, IL-17AF, IL-17F and IL-22. (B) Candidalysin secreted from 
C. albicans hyphae during oral epithelial cell invasion triggers the activation of c-Fos via p38-
MAPK pathway along with NF-B and PI3 kinase signaling pathway. These signals lead to the 
induction of IL-36 and IL-1 which target both epithelial cells and Type 17 cells to enhance Type 
17 response.  
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Table 1.1: Summary of host PRRs and PAMPS in anti-fungal immunity 
Family PRR Fungal PAMP Reference 
 
 
Toll like receptors (TLR) 
TLR2 Phospholipomannan,  glucan [42, 59, 60] 
TLR3 Double-stranded RNA [61] 
TLR4 O-linked mannan [46, 62] 
TLR9 DNA CPG motifs [63] 
 
 
 
C-type lectin receptors (CLR) 
Dectin-1 -1,3-glucan [39, 64] 
Dectin-2 High mannose structures,  
 mannans 
[65, 66] 
Mannose receptor Mannan [67] 
Mincle High mannose structures [68] 
Galectin-3 -1,2-mannosides [69] 
DC-SIGN High mannose structures [70] 
Nod-like receptors (NLR) NLRP3 DAMPS? [56] 
NLRC4 DAMPS? [57] 
 NLRP10 DAMPS? [55] 
Others EphA2 -glucans [58] 
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1.2.3 The oral epithelium; more than just a physical barrier 
The oral cavity is the gateway to the GI tract and also partly connects the nasopharyngeal 
passage. Hence the oral cavity is a major connection to the head, digestive and respiratory tract. 
Unlike the lung and skin that can become fibrosed in response to pathological insults and persistent 
inflammation, the oral mucosa is adept at responding to insults (including invading pathogens, 
food and allergens, mechanical stress etc.) and restrains excessive inflammation [3, 71]. 
Furthermore, compared to the skin, the oral mucosa has intrinsic abilities to heal and repair faster. 
These features are partly attributed to its unique abilities to regulate inflammation, modulate stem 
cell, proliferation and differentiation programs while maintaining efficient remodeling of oral 
epithelial cells (OECs) [72, 73]. Moreover, the oral mucosa is poised at basal state and primed to 
respond to oral mucosal assaults [71]. The oral epithelium is therefore a formidable physical barrier 
with enormous capacity not only to limit microbial invasion and dissemination but also to instigate 
a myriad of immunosurveillance signaling cascades to limit invading pathogens and protect 
underlying tissues.  
The organization and structure of the oral mucosa is key to its functions. The stratified 
squamous epithelia of the oral mucosa consists of specialized mucosa (tongue papillae, taste buds), 
lining mucosa (inner lip surface, buccal mucosa, soft palate and the floor of the mouth) and the 
masticatory mucosa (gingiva, hard palate, and dorsum of tongue) (Fig. 1.3) [3, 74]. These 
specialized mucosae have sensory abilities that are facilitated by motor and sensory nerve 
innervation to allow movement and perception of stimuli including taste, irritation and heat. The 
masticatory mucosae are distinguished from the lining mucosa by virtue of their toughness and 
resistance to stress. While the masticatory mucosae are keratinized to deal with persistent exposure 
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to physical stress, the lining mucosa are less subject to physical stress and are accordingly 
nonkeratinized or only partly keratinized [3, 75, 76].  
Depending on the cell type and stage of differentiation, OECs express unique pairs of 
keratins which function as cytoskeletal proteins to maintain the integrity of the oral epithelium 
[75]. The oral epithelium is compartmentalized mainly into the underlying basal epithelial layer 
(BEL), an intermediate layer, and a post-mitotic overlying suprabasal epithelial layer (SEL) (Fig. 
1.3).  
 
Figure 1.3: Histology of the oral mucosa 
The oral cavity is subject to allergenic, masticatory and pathogenic stress and the stratified 
squamous epithelium of the oral cavity is adapted to respond to these insults. Keratinizing 
epithelium of the tongue is made of 2 main layers, which express unique sets of keratins; K4 and 
K13 in the supra basal epithelial layer and K5, K14 and K19 in the basal epithelial layer. The 
dorsum of the tongue also has several papillae containing taste buds for taste sensation.  
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The proliferative basal epithelial cells of most epithelial surfaces including the oral mucosa 
mostly express keratin 5 (K5) and keratin 14 (K14) and harbor epithelial stem cells. Emerging 
studies have shown the presence of Lrig1+ and Lrig5+ stem cells in the oral basal epithelium [77-
79]. Cells of the BEL undergo a program of coordinated self-renewal and differentiation to give 
rise to terminally differentiated cells, which replenish the overlying SEL [80-82]. The oral SEL, 
on the other hand, mostly expresses keratin 4 (K4) and keratin 13 (K13). Additional keratins 
including keratin 6 (K6), keratin 16 (K16), and keratin 2p (K2P) that mark the differentiated 
epithelium are expressed in the SEL [80]. The differentiated SEL makes the first contact with 
invading hyphae and is damaged during invasion. The proliferation and subsequent differentiation 
of the basal epithelial cells is therefore required to replenish, maintain and restore oral mucosal 
integrity and immunity after infection or injury. 
Oral epithelial cells are key to oral immunity and are important for recognizing and 
instigating early immune responses against microbes [83]. During OPC, oral epithelial cells sense 
the transition of C. albicans from commensal yeast to virulent hyphae to dictate downstream 
signaling cascades [34]. This early recognition is mediated through receptors including HER2/Neu 
and EGFR [23]. EGFR binds to candidalysin to trigger epithelial damage and cFOS mediated host 
immune responses [34, 36, 37]. This immunosurveillance response of OECs to C. albicans 
promotes the induction of innate cytokines (including IL-1α/β, IL-36, CCL20, G-CSF (granulocyte 
colony-stimulating factor), GM-CSF (granulocyte-macrophage colony-stimulating factor), and 
antimicrobial peptides (β-defensins, S100A8/9) [37, 84, 85]. This tissue microenvironment 
promotes IL-17 expression and proliferation of IL-17 producing natural Th17 (“nTh17”) cells [37, 
86]. IL-17 drives canonical NF-B pathway and MAPK (mitogen activated protein kinase) 
cascades to further promote the induction of neutrophil-recruiting factors, myeloid and lymphoid 
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chemoattractants and antimicrobial peptides [87]. In particular, IL-17RA signaling in the SEL is 
critical for IL-17-mediated protection and induction of DefB3 (-defensin 3) during OPC [74, 88]. 
Thus, by virtue of its structure and strategic positioning, the oral epithelium is able to recognize 
and initiate a cascade of immunosurveillance programs to respond to oral C. albicans infection. 
1.2.4 Th17/IL-17R signaling is at the center of antifungal immunity 
1.2.4.1 The role of Th17/IL-17 signaling; evidence from human PIDs and murine data 
Increased incidence of oral thrush in HIV+ patients and the strong correlation to low CD4 
counts opened up investigations into T helper cell lineages and their associated cytokines in 
antifungal immunity [4]. Initial studies conducted before the discovery of Th17 cells had led to the 
conclusion that Th1 and Th2 lineages were the mediators of antifungal immunity [89, 90]. Studies 
with athymic mice further supported the role of T cell mediated immunity in OPC [91]. However, 
depletion of CD4 or CD8 T cells in a murine OPC model did not exacerbate susceptibility to OPC 
[92] although adoptive transfer of Candida-specific T cells conferred protection against 
disseminated candidiasis [93]. These studies indicated the role of both innate and adaptive T cells 
in oral antifungal immunity, but the specific Th cell lineage and associated cytokines were not 
convincingly defined. 
The observation that athymic mice with low T cell numbers succumbed to oral C. albicans 
challenge supported the role of T cell-mediated immunity in OPC [91]. Studies using Il12p40-/- (a 
common subunit shared with Il23p19 to form functional IL-23 and with Il12p35 to form functional 
IL-12) mice led to the interpretation that IFN-producing Th1 cells were the primary mediators of 
oral antifungal immunity. Inconsistent with this idea, however, was the observation that IFN-/- 
mice were resistant to OPC [94]. This conundrum was resolved when it was shown that Il23p19-/- 
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but not Il12p35-/- are susceptible to OPC, thereby demonstrating that the increased fungal burden 
in Il12p40-/- was due to the loss of IL-23 rather than IL-12 [74, 95]. Additional studies with mice 
lacking IL-17RA or IL-17RC demonstrated increased susceptibility to OPC, thereby shifting the 
dominant paradigm from a Th1-dominant response to a Th17-dominated response [74, 95, 96]. 
Although IL-23 is not required for Th17 differentiation, it is required for maintaining effector Th17 
functions, and IL-23-deficient mice are susceptible to OPC [74, 97]. Consistent with the protective 
role of the Th17/IL-17R axis in oral antifungal immunity, onset of AIDS in HIV+ patients is 
characterized by a sharp decline in CD4 T cells and a concomitant increase in oral thrush incidence. 
Early depletion of Th17 cells observed in HIV and SIV (simian immunodeficiency virus) studies 
and the incidence of oral thrush further added to the evidence supporting the vital role of Th17 
cells in OPC [98]. Intriguingly, the decreased CD4 count is neither associated with incidence of 
invasive candidiasis in HIV+/AIDS patients nor VVC in HIV+/AIDS women [99]. Together, these 
findings highlight the prominent roles of IL-17 in antifungal immunity with particular beneficial 
impact in the oral cavity. 
Findings from human primary immunodeficiency syndromes (PIDs) confirmed the 
paradigm regarding a vital protective role of the IL-17/TH17 axis in oral antifungal immunity [3, 
100]. Job’s syndrome/ autosomal dominant hyper immunoglobulin E syndrome patients (AD-
HIES) are characterized by mucocutaneous candidiasis, pulmonary infections, staphylococcal 
abscesses, eczema and abnormalities in bone and connective tissue. These patients possess 
mutations in the DNA binding- or SH2 domains of STAT3, which lead to decreased retinoic-related 
orphan receptor (ROR)- expression (the Th17-specific “master” transcriptional regulator) and 
decreased frequencies of Th17 cells [101, 102]. Other HIES patients with similar phenotypes were 
also identified with mutations in TYK2, which encodes a kinase important for activation of STAT3 
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and other STATs [103]. Gain-of-function mutations in STAT1 also predispose patients to 
autosomal dominant chronic mucocutaneous candidiasis (AD CMC) linked to impaired Th17 
immunity. This PID increases STAT1-dependent cellular responses due to delayed 
phosphoSTAT1 (pSTAT1) inactivation, even in the presence of STAT3-activating Th17 
polarizing cytokines. Impaired STAT3 activation ultimately is associated with decreased               
IL-17A-, IL-17F- and IL-22-producing Th17 cell frequencies [104, 105]. Similarly, autoimmune 
polyendocrinopathy candidiasis ectodermal dystrophy (APECED, also known as autoimmune 
polyendocrine syndrome 1, APS1) patients carry AIRE mutations which impair central tolerance. 
These patients are characterized by multiple autoimmune endocrinopathies, which are often 
preceded by CMC. The latter is attributed to the increase in circulating autoantibodies against IL-
17A, IL-17F and IL-22 [106-108]. Further direct evidence came from discoveries of human loss 
of function mutations in IL17RA, IL17RC, IL17F, ACT1, RORC, CARD9 and CLEC7A (encoding 
Dectin-1), which predispose patients to CMC and/or disseminated candidiasis [109-112]. Thus far, 
the overwhelming majority of murine data and data from humans with the described PIDs have 
supported the role of Th17/IL-17 signaling in oral antifungal immunity.  
1.2.4.2 IL-17 family; cellular sources and induction requirements in OPC 
The IL-17 family of cytokines consists of six structurally related members, namely IL-17A, 
IL17B, IL-17C, IL-17D, IL-17E (IL-25) and IL-17F. Of these, IL-17A and IL-17F have the closest 
homology (~60%) and are nearly always produced together. Unlike the other members of the 
family, IL-17A and IL-17F are encoded by closely linked genes and exist as homodimers and or 
heterodimers with different binding affinities to their cognate receptor [IL-17A/A (IL-17A) > IL-
17A/F (IL-17AF)> IL-17F/F (IL-17F)]. IL-17A is the best characterized member of the family and 
is often produced by Th17 subset of CD4+ T cells, although IL-17A-producing CD8+ T cells (Tc17) 
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have also been described. IL-17 is also produced by several innate immune cells including innate-
acting TCR+ cells (natural Th17 cells, “nTh17”),  cells, group 3 innate lymphoid cells 
(ILC3s), natural killer T (NKT) cells [86, 113, 114]. Although controversial, some myeloid cells 
and B cells have also been shown to produce IL-17 [115]. These innate and adaptive sources of 
IL-17 are collectively called Type 17 cells. Type 17 cells also produce other cytokines such as IL-
22, and GM-CSF (granulocyte-macrophage colony-stimulating factor).  
In the context of acute OPC, nTh17 cells undergo proliferative expansion and are the 
largest source of IL-17, followed by  cells [37, 86]. This is in contrast to a skin C. albicans 
infection model where  cells instead are the major source of IL-17 [116]. One other group has 
reported IL-17 expression from ILC3s in OPC, but this appears to be a minor population [117]. 
RORt is the lineage-defining ‘master transcription factor’ for Type 17 cells and works in 
conjunction with STAT3 to promote Th17 differentiation and effector functions. 
RORt  deficiency impairs IL-17 production in all Type 17 cells, and Rorc-/- mice are susceptible 
to OPC [86]. In contrast, STAT3 is not required in CD4 T cells for IL-17-mediated immunity to 
acute OPC [86] but is required for conventional Th17 cells. Type 17 cells also express the 
chemokine receptor CCR6, which binds to the mucosal ligand CCL20. The CCR6/CCL20 axis is 
therefore thought to promote recruitment of Type 17 cells to the target mucosal tissue in response 
to insults and explains the enrichment of Type 17 cells in mucosal tissues. However, CCR6 is 
dispensable for expansion of nTh17 cells in acute OPC, and CCR6-/- mice are resistant to OPC 
[37]. This could mean that CCR6 may instead be important in conventional Th17 cells in adaptive 
immune settings but this has not been proven experimentally.  
Generally, IL-17 expression in Type 17 cells during OPC is dictated by Th17 polarizing 
cytokines IL-23 and IL-1, which are released in response to activation of host PRRs by pathogen-
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derived PAMPS. Unexpectedly, prototypical fungal PRRs such as Dectin1 or TLR2, which are 
important in driving conventional Th17 polarization, were dispensable for innate Il17a induction 
and expansion of nTh17 cells [37, 42]. Instead, Il17a induction and nTh17 expansion in acute OPC 
required the C. albicans toxin candidalysin [34, 37]. In contrast, while the CLR downstream 
adaptor CARD9 is not required for protection against acute OPC, it is protective in T cell recall 
OPC settings and required for efficient IL-17A expression. Thus, there appear to be specific 
requirements for Il17a induction and Type17-mediated protection in innate and adaptive OPC 
settings. 
1.2.4.3 IL-17 signal transduction: The case of OPC 
The IL-17 family of cytokines signal through 5 receptors, IL-17RA-ILRE. IL-17RA is a 
common receptor which forms complexes with the other IL-17 receptors to transmit signals from 
the IL-17 family. Homodimers/heterodimers of IL-17A and IL-17F signal through the IL-17RA-
IL-17RC receptor complex [118]. A recent report suggested that IL-17A homodimers in addition 
may signal through the IL-17RA/IL-17RD complex, at least in keratinocytes [119]. Although not 
yet determined for Il17rd-/- mice, both Il17ra-/- and Il17rc-/- mice are susceptible to OPC [74, 96]. 
IL-17R-mediated signaling requires the recruitment of the cytosolic adaptor Act1, which 
distinguishes the IL-17R pathway from other signaling cascades such as IL-1R/TLR pathways 
[113, 120, 121]. Most studies in disease settings have demonstrated roles for IL-17RA and Act1 
in the non-hematopoietic compartment [3, 122]. Consistent with this, loss of IL-17RA in K13-
expressing superficial OECs of the tongue recapitulated the susceptibility of global Il17ra-/- mice 
to OPC [88]. Hence, superficial OECs dominantly control IL-17R-mediated responses against 
OPC. 
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Figure 1.4: IL-17 signaling in OPC 
Activation of the IL-17 receptor results in the recruitment of ACT1 and TRAFs to the receptor. 
TRAF6 activation triggers the induction of transcription factors including NF-B, I C/EBP, 
C/EBP and AP-1. The ACT1-TRAF5-TRAF2 complex on the other hand promotes post 
transcriptional control of IL-17 target genes partly through RNA binding proteins (RBP). In OPC, 
this IL-17 dependent signaling activates neutrophil recruiting chemokines and antimicrobial 
peptides (AMPs) to promote fungal clearance.  
 
Upon engaging its receptors (Fig. 1.4), IL-17 exerts two broad signaling events; de novo 
transcription and or post-transcriptional regulation of target mRNAs. New transcription is 
facilitated by the recruitment of Traf6 to Act1-bound IL-17RA and its subsequent ubiquitination 
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[113]. These signaling events ultimately promote NF-B, C/EBP C/EBP and MAPK dependent 
signaling cascades. In IL-17-induced NF-B signaling, the transcription factor I (encoded by 
Nfkbiz) is a central regulator of IL-17 target genes, and many IL-17 target genes possess I  
binding sites [123-126]. Similar to I C/EBP and C/EBP binding sites are present and 
required in promoters of some IL-17 target genes. Although less dominant and cell type-dependent, 
IL-17 also activates the mitogen-activated protein kinase (MAPK) pathways including 
extracellular signal regulated kinase (ERK1/2), p38 and JUN N-terminal kinase (JNK) [113, 127, 
128]. In addition to inducing transcription of target genes, IL-17 modulates target transcripts via 
post transcriptional events through ACT1-TRAF2-TRAF5 interactions. IL-17 induced post-
transcriptional control of target genes is achieved through alterations in mRNA stability and or 
translation through RNA binding proteins (such as MCPIP1/Regnase-1, ARID5A, HuR), micro 
RNAs (such as miR-23b, miR30a) and ubiquitin mediated signaling. Together, these events are 
thought to enhance the profound biological consequences of IL-17 signaling [113]. 
IL-17 promotes antifungal immunity in OPC through a classic panel of genes including 
neutrophil recruiting factors such as the CXC chemokines (CXCL1, CXCL2 and CXCL5), G-CSF, 
myeloid and lymphoid chemoattractants (CCL20 and MCP1) and antimicrobial peptides (-
defensins, lipocalin 2 and S100A8/9) [74, 88]. Although there are varied reports on the role of IL-
17 signaling in neutrophil recruitment during OPC [74, 88, 129], Ccr2-deficient mice (which lack 
the common CXC chemokine receptor) or mice in which neutrophils are depleted exhibit 
exacerbated OPC [130]. Similarly, Defb1-/- and Defb3-/- mice are also susceptible to OPC, with 
comparable fungal burdens to Il17ra-/- mice [88, 131]. However, CCL20, a lymphoid 
chemoattractant with antimicrobial properties, is not critical for oral antifungal immunity, as 
neither depletion of CCL20 nor Ccl20 deficiency increased susceptibility to OPC [132]. IL-17 is 
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also thought to act on salivary gland epithelial cells to induce expression of AMPs such as histatins 
(only in humans) and −defensins in saliva. Consequently, decreased AMP expression in HIES 
and xerostomia patients partly accounts for the incidence of oral thrush [133, 134]. Together these 
findings support a strong role for IL-17 target genes in oral antifungal immunity.  
Additionally, other cytokines including IL-36 have been shown to be important in driving 
oral antifungal immunity [135]. During hyphal invasion, candidalysin-induced epithelial damage 
promotes the production of IL-1, IL-36 and other cytokines. In turn, IL-1 and IL-36 drive Type 17 
immunity and nTh17 proliferation through two parallel pathways; while IL-1 drives IL-17 
expression, IL-36 promotes IL-23 expression [37, 136]. Thus, while IL-17 is clearly playing a 
dominant role, effective antifungal immunity is actually a concerted effort of multiple cytokines 
and pathways that reduce fungal burdens while limiting exacerbated inflammation.  
1.2.5 IL-22/IL-22RA1 signaling axis in OPC 
1.2.5.1 IL-22; cellular sources and induction requirements  
IL-22 is a member of the IL-20 subfamily of IL-10 family cytokines (consisting of 8 
members, namely IL-10, IL-19, IL-20, IL-24, IL-26, IL-28A, IL-28B and IL-29). Like humans, 
murine Il19, Il20 and Il24 are located on chromosome 1q32 [137]. Il22, Il26 and IFN are found 
within the same vicinity on chromosome 12q15 although Il26 is absent in mouse genome [138]. 
As a family, these cytokines are classified based on their structural similarity, shared receptors and 
downstream signaling. IL-10 and IL-22 are the best studied cytokines in this family with about 
22% homology in mice and 25% homology in humans, respectively. IL-22 consists of six alpha 
helices (A-F) and an N terminal helix, which are compacted to form a left-handed helical cytokine. 
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IL-22 is initially synthesized as a 179 amino acid polypeptide that undergoes proteolytic cleavage 
and glycosylation to generate a mature 146 amino acid bioactive protein [139, 140].  
IL-22 is produced by innate and adaptive immune cells including   cells,  T cells, 
NKT cells and innate lymphoid cells (ILCs). Although less common, some studies have also 
reported IL-22 expression in neutrophils, macrophages and fibroblasts [141, 142]. The dominance 
of these cellular sources of IL-22 are context-dependent. In addition to their primary cytokines, 
IL-22 expression has been reported in Th1 and Th17 cells. Additionally, a lineage of  CD4 
 cells that produce only IL-22 has been described, sometimes called Th22. In mice, however, T 
cell-derived IL-22 is mostly ascribed to Th17 cells [143-146]. Similar to CD4 T cells, IL-22 
production has been identified in a subset of CD8 T cells that produce IL-22 alone or both IL-17 
and IL-22 [147-150]. In the context of fungal infections, C. albicans-specific IL-22-producing 
Th17 cells and Th22 cells have been reported in human peripheral blood mononuclear cells 
(PBMC), and are thought to be more abundant than C. albicans-specific IL-17 producing Th17 
cells [151]. Additionally,  T cells also produce a significant amount of IL-22. While IL-17-
producing  T cells have been reported in murine OPC [86], and are expanded in HIV+ patients 
[152], there are few reports of IL-22 expressing  T cells in the context of OPC.  
Another principal source of IL-22 are ILCs. ILCs are a heterogenous population of cells 
lacking rearranged T cell and B cell receptors. Similar to Th1, Th2 and Th17 subsets, ILCs are 
classified as ILC1, ILC2 and ILC3 based on their expression of lineage defining transcription 
factors and cytokines. Group 3 ILCs (ILC3) produce IL-17 and IL-22 and can be further broadly 
classified based on their expression of natural killer cell cytotoxicity receptors (NCRs) such as 
Nkp44 in humans [153] and Nkp46 in mice [154, 155]. Like Th22 cells, a subset of ILC3s (initially 
named NK22) cells have been described which only produce IL-22 [153, 156]. While IL-17-
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expressing ILC3s have been described in OPC [117], it is not known whether these cells produce 
IL-22. IL-22 producing NKT cells have also been described [157, 158] but there is not yet any 
report of IL-17 or IL-22 producing NKT cells during OPC. 
Optimal production of IL-22 is dependent on a number of polarizing cytokines and 
transcription factors. Similar to IL-17-producing Type 17 cells, IL-23 signals on ILC3s,  T cells 
and NKT cells to promote IL-22 expression [146, 159-161]. Not surprisingly, Il22 deficiency 
mirrors Il23 deficiency in many settings [74, 162, 163]. Dendritic cells are a major source of IL-
23. Through TLR2, TLR4, TLR5, TLR7, TLR8 and Dectin1/2 activation via their respective 
PAMPS, Th17 polarizing cytokines (IL-1, IL-21, IL-6, TGF-  and IL-23) are secreted from 
dendritic cells [142, 164, 165]. IL-23 promotes STAT3 activation and subsequent upregulation of 
RORT in Type 17 cells to induce not only IL-17A and IL-17F but also IL-22 [146, 161, 166, 
167]. In the skin, nociceptive nerves promote IL-23 production from dermal dendritic cells to drive 
Type 17 cell polarization [116, 168]. A subset of nociceptive nerves (TRPV1+ neurons) was 
recently shown to be sufficient to initiate Type 17 inflammation [169]. IL-1 from multiple cell 
types also drives IL-22 production independently of IL-23, which can synergize to further increase 
IL-22 output [170, 171]. Additionally, the aryl hydrocarbon receptor (AhR) directly regulates Il22 
expression and Th17 development in the presence of AhR ligands, at least in the gut. AhR ligands 
include dietary or microbiota derived products such as indol-3-carbinol, 6-formylindolo(3,2-b) 
carbazole (FICZ) as well as factors such as physical shear stress, cyclic AMP and Ca2+ [142, 172, 
173]. It is therefore evident that, while IL-17 and IL-22 share many similar sources and induction 
requirements, the dominant cellular sources are context-dependent.  
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1.2.5.2 IL-22 receptor signaling 
Members of the IL-10 family signal through heterodimeric receptors consisting of 
 and  chains. While the −chains (IL-10RA, IL-20RA, IL-22RA1) have higher ligand binding 
affinity, the  chains (IL-10R2 and IL-20R2) have lower binding affinity and often undergo a two-
step binding process with their respective cytokines. The initial ligation to the −chain creates a 
high affinity complex which subsequently binds to the corresponding −chain. Ligand specificity 
and cellular response is therefore defined by the expression of the −chains [174-177]. IL-10 
signals through IL-10RA and IL-10RB receptor complex (Fig. 1.5) while IL-19, IL-20 and IL-24 
signal through IL-20RA and IL-20RB receptor complex [178, 179]. In addition, IL-20 and IL-24 
but not IL-19 are able to signal through the IL-22RA1 and IL-20RB receptor complex. IL-26 
signals through the IL10RB-IL20RA heterodimer, while IL-28A, IL28B and IL-29 signal through 
the IL-10RB-IL-28 receptor. In contrast, IL-22 signals through a complex consisting of IL-22RA1 
and IL-10RB. While IL-10RB is ubiquitously expressed, IL-22RA1 is mostly expressed in non-
hematopoietic cells, thus restricting its functional roles mostly to the stromal compartment [139, 
142]. Recent studies, however, have indicated  IL-22RA1 expression in lung macrophages during 
K. pneumonia and M. tuberculosis infection [180, 181]. Thus, although the majority of available 
data support the roles of IL-22RA1 in non-hematopoietic cells, it is likely that perturbations in 
specific disease contexts could change receptor localization patterns, a subject that needs further 
investigation. 
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Figure 1.5: IL-10 family cytokines, receptors and signaling 
IL-22 is a principal member of the IL-20 subfamily of IL-10 family cytokines. IL-22 signals 
through the receptor complex consisting of IL-22R1 and IL-10R2. IL-22BP (IL-22R2) is a soluble 
IL-22R1 decoy receptor which negatively regulates IL-22 signaling. IL-10R2 is shared with the 
receptors for IL-10, IL-26, IL-28 and IL-29. IL-22R1 can also pair with IL-20R2 to form the 
receptor complex for IL-20 and IL-24. Additionally, IL-20, IL-24 and IL-19 signal through IL-
20R1- IL-20R2 complex. IL-22 signaling activates STAT3 as well as STAT1, STAT5 and 
p38/MAPK signaling in other contexts to drive genes important for proliferation, tissue repair, cell 
cycle progression, antimicrobial peptides etc. 
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Upon binding to the IL-22 receptor complex, the receptor-associated tyrosine kinases Jak1 
and Tyk2 are cross-phosphorylated and activated. In turn, activated Jak1/Tyk2 phosphorylate 
STATs. Although STAT3 is the primary mediator of IL-22 signaling, STAT1 and STAT5 
phosphorylation have been observed in response to IL-22 stimulation [182, 183]. Like the other 
STATs, STAT3 phosphorylation at the tyrosine residue at position 705 dictates its dimerization, 
nuclear translocation and transcriptional activity. Serine 727 phosphorylation on the other hand 
enhances STAT3 transactivation and drives non-canonical transcriptional functions of STAT3 in 
the mitochondrion and endoplasmic reticulum [182, 184]. Beside STATs activation, IL-22 also 
activates the MAP kinase and p38 pathways [185-188].  
1.2.5.3 Regulation of IL-22 signaling 
IL-22 signaling is regulated at multiple levels. At the level of the receptor, GSK3 
phosphorylates Serine 410 and 414 on IL-22RA1 to prevent proteasomal degradation. The 
resulting enhanced stability tends to promote IL-22 signaling [189]. IL-22 also binds to a soluble 
IL-22 receptor subunit called IL-22 binding protein (IL-22BP) or IL-22RA2. IL22BP shares 
overlapping binding sites with IL-22RA1 and binds to IL-22 with affinity about 1000-fold higher 
than the membrane bound IL-22RA1. IL-22BP therefore competes with IL-22RA1 to bind to IL-
22 and functions as a negative regulator of IL-22 signaling [142, 180, 190]. Similarly, suppressor 
of cytokine signaling (SOCS) proteins serve as key regulators of IL-22/JAK/STAT pathway by 
negatively regulating STAT signaling. SOCs 1-3 and cytokine inducible SH2-containing-1 (CIS-
1) are the best characterized members of the family. While CIS-1 negatively regulates 
JAK2/STAT5 pathway, SOCS1 and 3 negatively regulate STAT3 signaling. SOCS1-3 and CIS 
proteins are therefore aberrantly expressed in a number of inflammatory conditions and cancer 
settings where their activities serve to potentiate JAK/STAT signaling [191, 192]. Protein 
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inhibitors of activated STATs (PIAS) family proteins also negatively regulate STAT dependent 
transcription. While PIAS3 negatively regulates STAT3 driven transcriptional activity, PIAS1 
together with other transcriptional repressors block STAT1 signaling by limiting binding to target 
DNA sequences [193, 194]. Additionally, other factors including activating transcription factor 3 
(ATF3) have emerged as positive regulators of IL-22 signaling in inflammatory bowel disease 
(IBD). IL-22 induced ATF3 regulates STAT3 signaling by negatively targeting protein tyrosine 
phosphatases (PTPs) such as SHP2 and PTP-Meg2 which are needed to dephosphorylate activated 
STAT3 into inactive STAT3 [195]. Together, these reports reveal a tightly regulated program to 
control IL-22 signaling both upstream and downstream of IL-22RA1. Consequently, failure to 
enforce this regulatory balance could have dire consequences.  
1.2.5.4 IL-22 signaling in pathophysiology and tissue regeneration 
Studies in liver, lung, skin, thymus, pancreas, kidney, gastrointestinal tract, heart, adipose 
tissue, breast and eye suggest that IL-22 exerts complex, context-dependent effects under 
pathophysiological conditions [6, 142, 196]. Generally, IL-22-mediated protection against 
hepatitis, pancreatitis, colitis, genotoxic stress and thymic injury are attributable to its tissue repair 
and regenerative properties on target tissues [140, 197, 198]. This repair process is often driven 
through healthy tissue proliferation and synthesis of antimicrobial peptides. However, in other 
settings with chronic IL-22 exposure such as psoriasis, IL-22 drives hyperproliferation and 
inflammation through the expression of proinflammatory mediators such as IL-1, IL-6, G-CSF and 
GM-CSF [139, 197, 199]. Fine balance is therefore key to determine the physiological outcome of 
IL-22, whether protective or pathological. The context-dependent role of IL-22 is also determined 
by other cytokines in the tissue microenvironment. Type 1 interferons tend to shift IL-22-mediated 
STAT3 signals to STAT1 responses [200]. Other cytokines including IL-17, IL-19, TNF- IL-
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1 and IL-36 exert additive or synergistic responses with IL-22 [201-203]. Hence, the 
physiological outcomes of IL-22 are largely influenced by the specific tissue microenvironments 
and the contributions of other available cytokines and regulatory factors. 
The physiological outcomes of IL-22 are highlighted by its roles in different tissues and 
disease contexts. These outcomes help to provide clearer understanding of the underlying 
mechanisms. In human gingival fibroblasts, IL-22 cooperates with IL-1 to induce CCL20 
expression and subsequent Th17 recruitment to promote periodontal disease [204]. In a psoriatic 
skin inflammatory model, combinations of IL-17A, IL-22, IL-1 OSM and TNF- recapitulated 
features of psoriasis, including increased chemokine and AMP production [205]. IL-22 also 
promotes keratinocyte proliferation, migration and tissue remodeling. During epithelial repair, IL-
22-induced matrix metalloproteinases (MMP1 and MMP3) are important for epithelial migration 
[188]. In addition, IL-22 limits keratinocyte differentiation and maturation by inhibiting expression 
of differentiation markers such as keratins (KRT1, KRT10), profilaggrin, involucrin, loricin, 
kallikrein 7 and desmocollin [142, 188, 206]. Similar to the skin, IL-22 acts on the lung epithelium 
to induce AMPs (such as lipocalin 2 and  defensin 2) and chemokines, promote proliferation and 
repair of the lung epithelium after injury [159]. These activities of IL-22 on the lung epithelium 
are important in driving protection against Streptococcus pneumoniae and Klebsiella pneumonia 
infections [159, 207].  
IL-22 can however exert opposing functions even with infections with the same pathogen, 
and other facets of IL-22 mediated mechanisms are beginning to emerge. While IL-22 is protective 
against acute Aspergillus fumigatus lung infection [208], IL-22 drives lung pathology during 
chronic exposure [209]. In a bleomycin-induced lung injury model, IL-22 ameliorated disease 
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severity only in the absence of IL-17A, because the presence of IL-17A exacerbated airway 
inflammation [210, 211].  
In addition to driving changes in epithelial cells/keratinocytes, IL-22 targets stem cells. IL-
22 acts on hepatocytes and liver stem cells to induce proliferation and regeneration through the 
induction of proteins such as Bcl-2, Bcl-XL, cyclin d-dependent kinase 4 (CDK4), cyclin D1, c-
myc and p2 [212-215]. Evidence of IL-22 mediated protection also exists for the gastrointestinal 
tract where it is important for gut inflammatory disorders, antimicrobial immunity, and cancer 
immunity [142, 153]. A recent publication showed that in response to genotoxic stress, IL-22 
promotes DNA damage response in intestinal stem cells, which is important for reducing the 
incidence of colon cancer [216]. In addition to the classical roles of IL-22 in mucosal epithelia, 
IL-22 also acts on the stromal environment in secondary and tertiary lymphoid tissues to control 
lymphocyte effector functions. During thymic injury, IL-22 promotes the regeneration of thymic 
epithelial cells to restore T cell function [140]. Similarly, IL-22 is thought to act on spleen and 
thymic stromal cells to restrain T cell activation during acute viral infection [217]. In line with this 
activity, IL-22 also acts on keratin 14 expressing cells of the skin to regulate MHCII expression 
and ultimately influence the responses to Staphylococcus epidermidis infection [218]. 
Collectively, these reports indicate that IL-22 does not only act on stromal cells of mucosal barriers 
to drive antimicrobial immunity and promote mucosal integrity but can also indirectly dictate the 
outcome of lymphocyte effector responses. 
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1.3 Summary 
Physiological outcomes of inflammation, injury and infections are dictated by the 
collective contributions of multiple factors; the secreted cytokines, the responding cells, as well as 
efficient regulatory mechanisms [219]. Thus, while some mediators may have more dominant 
roles, the overall outcomes are determined by the interplay of these multiple factors rather than a 
single cytokine, cell type or regulatory mechanism. This chapter discusses the current state of our 
understanding of oral antifungal immunity mainly from the perspectives of IL-17, IL-22, the oral 
mucosa and the underlying mechanisms at play.  
Both IL-17 and IL-22 are implicated in antifungal immunity and are thought to mainly act 
on non-hematopoietic cells. In view of their dominance in OPC settings, it is critical to understand 
their specificity and how they collectively work in concert to integrate multiple signals for the 
benefit of the host. These advancements will shed better light on the oral mucosa and immunity in 
the oral cavity particularly with respect to IL-22.  
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2.0 Materials and Methods 
2.1 Materials 
2.1.1 Mice 
Il22TdTomato, Il22ra1fl/fl, K13Cre, Card9−/−, K14CreERT2, STAT3fl/fl, Saa1/2, Il23r-/- mice 
and Act1-/- were described [88, 220-224]. Il17ra-/- mice were from Amgen and Il22-/- mice were 
from Genentech. All other mice were from JAX or Taconic Farms. Mice were on the C57BL/6 
background and housed in specific pathogen free (SPF) conditions. Experiments were performed 
on age-matched mice (6-10 weeks) of both sexes. Experiments were performed in accordance with 
protocols approved by the University of Pittsburgh IACUC and NIAID and followed guidelines in 
the Guide for the Care and Use of Laboratory Animals of the NIH. 
2.1.2 Cells and Cytokines 
Human TR146 OECs (ECAAC10032305) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM)–F12/15% fetal bovine serum as previously described [84]. Recombinant 
human IL-22 (PeproTech 200-22) was used at 100ng/ml. 
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2.1.3 Antibodies 
Antibodies used are listed in Table 2.1 
Table 2.1: List of antibodies 
Antibody Vendor Purpose Catalog # Dilution 
STAT3 Cell signaling Western blot 9139 1:1000 
pSTAT3 Cell signaling Western blot 
 IF 
9145 1:1000 
1:100 
c-Fos Cell signaling Western blot 2250 1:1000 
pC-Fos Cell signaling Western blot/ IF 5348 1:1000 
I Cell signaling Western blot 9244 1:1000 
pP65 Cell signaling Western blot 3033 1:1000 
P65 Cell signaling Western blot 8242 1:1000 
ERK Cell signaling Western blot 4695 1:1000 
pERK Cell signaling Western blot 9106 1:1000 
JNK Cell signaling Western blot 9252 1:1000 
pJNK Cell signaling Western blot 4668 1:1000 
-actin-HRP Abcam Western blot Ab49900 1:25000 
Keratin 14 Abcam 
Abcam 
Invitrogen 
IF  
Flow cytometry 
IF  
Ab181595 
 
Ab210414 
MA5-11599 
1:300 
1:5000 
 
Keratin 13 Abcam IF Ab92251 1:300 
IL-22RA1 R&D IF MAB42941 1:100 
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Table 2.1 continued 
Antibody Vendor Purpose Catalog # Dilution 
CD45 Pac Blue,  
AF 700 
Biolegend Flow cytometry 103125 
103128 
1:100 
CD45.1 FITC Biolegend Flow cytometry  110705 1:100 
CD45.2 PE Biolegend Flow cytometry 109807 1:100 
CD44 eFluor 450 eBioscience Flow cytometry 48044182 1:100 
CD4 APC Fire 750, 
Qdot 605 
Biolegend 
ThermoFisher 
Flow cytometry 100459 
Q10008 
1:100 
1:500 
CD11B AF 700 Biolegend Flow cytometry 101222 1:100 
Ly6G PE BD Flow cytometry 551461 1:100 
TCR 
FITC, PE, PerCP-
Cy5.5 
eBioscience 
Biolegend 
BD 
Flow cytometry 11596185 
109207 
560657 
1:100 
TCR eFluor 450, 
PE 
Invitrogen 
eBioscience 
Flow cytometry 48571182 
125781181 
1:100 
EpCAM 
FITC 
 Flow cytometry 11579182 1:100 
IL-17A 
APC, PE 
Invitrogen 
BD 
Flow cytometry 11717781 
559502 
1:100 
IFN- 
PE-CF594, APC 
BD Flow cytometry 562303 
554413 
1:100 
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2.1.4 qRT-PCR primers 
Primers for qRT-PCR were purchased from Qiagen and are listed in Table 2.2 
Table 2.2: List of commercial qRT-PCR primers 
Gene Symbol Organism Catalogue # 
Il17a Mouse QT00103278  
Il17f Mouse QT00144347 
Il22 Mouse QT00128324 
Il17ra Mouse QT00112063  
Defb3 Mouse QT00265517 
2.2 Methods 
2.2.1 Primary and Recall OPC Model 
C. albicans (CAF2-1, SC5314 and strains) were grown overnight for 16 hours in yeast 
extract peptone dextrose (YPD) broth at 30ºC with continuous agitation. C. albicans suspension 
was prepared to a final density of 2x107 cells/ml. Mice were anesthetized (100mg/kg Ketamine 
and 10mg/kg Xylazine in 0.9% sterile saline) and sublingually inoculated with pre-weighed 
(2.5mg) cotton balls saturated with C. albicans. Control sham mice were similarly inoculated with 
pre-weighed cotton balls soaked in PBS. Mice remained under anesthesia for 75 minutes after 
which the cotton balls were taken out. Mice were also administered 1ml of 0.9% saline before and 
after oral challenge. Anti-IL-22 Abs (Genentech, clone 8E-11) or control IgG1 (Bio X Cell) 
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(150ug) were injected i.p. on days -1, 0, 1, 2, 3 relative to infection. Anti-IL-17A or IgG2a control 
Abs (200ug) were from Janssen Research & Development LLC [225] and administered i.p. on 
days -1, 1, and 3 relative to infection. For primary OPC, mice were weighed daily until harvest on 
days 1, 2, 3, 4 or 5 post infection. One longitudinal half of the harvested tongue was collected, 
flash frozen in liquid nitrogen and stored at -80ºC for RNA extraction. The other half tongue was 
homogenized by mechanical disruption using a GentleMacs dissociator (Miltenyi Biotec). Tongue 
homogenates were plated in triplicate on YPD agar plates containing ampicillin, incubated at 30ºC 
for 48 hours and quantified by estimating colony forming units per gram (CFU/g) of tongue. For 
the recall infection model, mice were initially infected with C. albicans or inoculated with PBS as 
described above. After 6 weeks, mice were re-infected with C. albicans as described above and 
organs were harvested at days 1, 2 or 3 post infection. One longitudinal half of harvested tongue 
was homogenized for CFU enumeration and the other half stored for RNA extraction as described 
above. For histological analysis, longitudinal sections of harvested tongues were embedded in a 
cast with optimum cutting temperature (OCT) compound and subjected to temperature gradient 
freezing. The samples were kept frozen at -80ºC until they were sectioned. Cervical lymph nodes 
(cLN) were also harvested and manually homogenized in RPMI. The homogenate was filtered and 
the resulting single cell suspension was stained for flow cytometry or co-cultured with heat-killed 
(HK) C. albicans for quantification of secreted cytokine by ELISA. A summary schematic of the 
primary infection and recall infection is presented in Fig. 2.1. 
2.2.2 Bone marrow chimera 
Recipient mice [WT(CD45.1), Il22ra1-/-(CD45.2) and Il22-/-(CD45.2)] were put on 
antibiotics water (Sulfamethoxazole and Trimethoprim) beginning from day -1. Recipient mice 
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were irradiated (900rads) on day 0. Femoral/ tibial bone marrow (106) from donor mice (WT, 
Il22ra1-/-and Il22-/-) were i.v. injected into recipient mice. Mice were withdrawn from antibiotic 
water after 10 days. After 6 weeks, successfully reconstituted mice were subjected to OPC as 
described above 
2.2.3 Co-culture of cLN cells with HK C. albicans and quantification of secreted cytokines 
HK C. albicans (CAF2-1) extract was prepared by boiling 1ml of (~ 4x108 cells) overnight 
cultured C. albicans for 45 mins at 56ºC. CLN cells were plated at 106 cells/well in flat bottom 24-
well plates with or without 2x106 HK C. albicans in serum-free AIM V media (GIBCO, Invitrogen) 
containing 1X -Mercaptoethanol (1000X, GIBCO Invitrogen) and 20U/ml of IL-2. Co-cultures 
were incubated at 37ºC and 5% CO2 saturation for 5 days. Culture supernatants were harvested on 
day 5 and analyzed for secreted IL-17A and IL-22 by ELISA according to the manufacturer’s 
instructions (eBioscience). 
2.2.4 Flow cytometry 
Flow cytometry of tongue homogenates was performed as described [86]. Tongues were 
digested with DNase1 (1mg/ml, Roche), and Collagenase IV (0.7mg/ml) in HBSS at 37°C for 30 
minutes. Filtered cell suspensions were either stained directly or separated by Percoll gradient 
centrifugation. Antibodies were from eBioscience, BD Biosciences, BioLegend or Abcam and are 
listed in Table 2.1. Proliferation was assessed using the Foxp3/Transcription factor Buffer kit 
(eBioscience) with Ki67-APC/PerCP. To assess apoptosis, CD45-EPCAM+ cells were stained with 
caspase-3 apoptosis kit (BD Biosciences) according to the manufacturer’s instructions. For cell 
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cycle analysis, mice were intraperitoneally injected with 1 mg bromodeoxyuridine (Abcam, BrdU 
flow kit, BD Biosciences) on day 1 p.i. and tongues harvested 24 h later. Harvested tongues were 
digested as described above and the total single cell suspension was processed for BrdU analysis 
based on the instructions from the manufacturer. For assessment of intracellular cytokines after 
recall infection, cLN were harvested on days 2 or 3 p.i. . Single cell suspensions were prepared as 
described previously and stimulated with 50ng/ml phorbol 12-myristate 13-acetate (PMA) and 
500ng/ml ionomycin (Sigma-Aldrich) in the presence of Golgi plug (BD Biosciences) for 4 hours 
at 37ºC and 5% CO2 saturation. After staining for surface markers (CD45, CD3, CD4, CD44), 
samples were fixed, permeabilized and stained for IL-17A and IFN-. Samples were stained with 
GhostDye Violet 510 (TONBO Biosciences, CA) to exclude dead cells. Data were acquired on an 
LSR Fortessa and analyzed with FlowJo (Tree Star). 
2.2.5 Histology, immunofluorescence and immunocytochemistry 
Cryosections were stained following the Cell Signaling immunofluorescence protocol 
(https://www.cellsignal.com/contents/resources-protocols/immunofluorescence-general-
protocol/if). Briefly, slides were fixed by incubation in ice cold methanol followed by blocking 
with 5% goat serum (Life technologies #50062Z), 1% bovine serum albumin (BSA)(Sigma 
Aldrich #A7906) and 0.3% Triton X (Fisher #BP151). Samples were stained overnight with 
primary antibodies [IL-22RA1, Keratin 13, Keratin 14, Ki67 and anti-p-STAT3 (Tyr705)]. 
Samples were subsequently incubated with secondary fluorescence antibodies. Nuclei were 
stained with DAPI and slides were cover slipped. TUNEL staining was performed with an 
Apoptosis Detection kit (Millipore). Images were acquired on an EVOS FL microscope (Life 
Technologies). Tunnel+ cells were enumerated from 10 random fields per slide. 
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2.2.6 qPCR, RNA-Seq and GSEA 
Frozen tongue tissue was homogenized in 500μl of Qiazol lysis buffer (Qiagen) using a 
GentleMACS Dissociator (M-tubes, RNA-02 program, Miltenyi Biotec). Chloroform was added 
to the lysates and centrifuged. The upper aqueous layer was collected and RNA was subsequently 
extracted following instructions of the RNAeasy Mini Kit. RNA concentration was assessed using 
Nanodrop. Equal concentrations of mRNA from samples were reverse transcribed into cDNA 
using Superscript III First-Strand synthesis system (Invitrogen) by following the manufacturer’s 
protocol. Gene expression analysis by qPCR was done using Perfecta SYBR Green FastMix ROX 
(Quanta BioSciences) on a 7300 Real-Time PCR System (Applied Biosystems) and normalized to 
Gapdh [37]. Primers were from QuantiTect Primer Assays (Qiagen) and are listed in Table 2.2. 
For RNASeq, cDNA libraries were prepared from tongue RNA harvested day 1 p.i. (Nextera XT 
Kit) and RNASeq was performed on the Illumina NextSeq 500 platform by the Health Sciences 
Sequencing Core at the University of Pittsburgh. Sequencing reads were annotated and aligned to 
the UCSC mouse reference genome (mm10, GRCm38.75) using HISAT [226]. HISAT alignment 
files were used to generate read counts for each gene, and determination of differential gene 
expression was performed using the DE-seq package from Bioconductor [227]. Unbiased 
hierarchical clustering of differentially expressed genes with P<0.05 was calculated using CLC 
Genomics Workbench and Partekflow software. Relative expression values in heat maps are TPM 
(Transcripts per kilobase million). Partekflow and GSEA from the Broad Institute were used to 
calculate enrichment of genes in each set. Frozen tongue tissue was homogenized in 500μl of 
Qiazol lysis buffer (Qiagen) using a GentleMACS Dissociator (M-tubes, RNA-02 program, 
Miltenyi Biotec). Chloroform was added to the lysates and centrifuged. The upper aqueous layer 
was collected and RNA was subsequently extracted following instructions of the RNAeasy Mini 
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Kit. RNA concentration was assessed using Nanodrop. Equal concentrations of mRNA from 
samples were reverse transcribed into cDNA using Superscript III First-Strand synthesis system 
(Invitrogen) by following the manufacturer’s protocol. Gene expression analysis by qPCR was 
done using Perfecta SYBR Green FastMix ROX (Quanta BioSciences) on a 7300 Real-Time PCR 
System (Applied Biosystems). Primers were purchased from commercial vendors and are listed in 
Table 2.2 
2.2.7 Western blot 
TR146 whole cell lysates were prepared with 1% NP40 lysis buffer complemented with 
protease inhibitors (Roche), sodium orthovanadate and phenylmethylsulphonyl fluoride (PMSF). 
Samples were gently agitated on a vortex with intermittent cooling on ice and the total cell extract was 
obtained by centrifuging at 15000g for 10 minutes. Protein concentration was assessed using Pierce 
BCA Protein assay kit (Thermo Fisher Scientific). Lysates were boiled with 4X sodium dodecyl 
sulphate (SDS) at 95°C for 5 minutes. 30μg – 50μg of total protein was loaded in 10% homemade 
polyacrylamide gels.  
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3.0 Oral Epithelial IL-22 Signaling Licenses IL-17-Mediated Immunity to Oral Mucosal 
Candidiasis 
This is the author’s version of the work. Sections of this chapter have been adapted from 
the original work published in Science Immunology and is posted here with permission from the 
journal.  
Science Immunology, June 2020, Volume 5, Issue 48 
“Oral epithelial IL-22/STAT3 signaling licenses IL-17-mediated immunity to oral 
mucosal candidiasis”  
Felix EY Aggor 1, Timothy J. Break 2, Giraldina Trevejo-Nuñez 3, Natasha Whibley1, Bianca M. 
Coleman1, Rachel D. Bailey1, Daniel H. Kaplan 4, Julian R. Naglik 5, Wei Shan 6, Amol C. Shetty 
7, Carrie McCracken7, Scott K. Durum 6, Partha S. Biswas1, Vincent M. Bruno 7, Jay K. Kolls 8, 
Michail S. Lionakis 2, Sarah L. Gaffen 1* 
1 Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh PA, 
USA 
2 Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National 
Institute of Allergy and Infectious Diseases, NIH, Bethesda Maryland, USA 
3 Division of Infectious Diseases, University of Pittsburgh, Pittsburgh PA, USA 
4 Department of Dermatology, University of Pittsburgh, Pittsburgh PA, USA 
5 Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, 
King’s College London, London, United Kingdom 
6 Cytokines and Immunity Section, Cancer and Inflammation Program, National Cancer Institute, 
NIH, Frederick MD, USA 
7 Institute for Genome Sciences, University of Maryland, Baltimore, MD, USA  
8 Center for Translational Research in Infection and Inflammation, Tulane University, New 
Orleans, LA, USA 
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3.1 Background 
Although IL-17 is the eponymous cytokine of Th17 cells and other “Type 17’ lymphocytes, 
IL-22 is also characteristic of these cells [228]. Multiple studies indicate that IL-22, like IL-17, 
helps control oral candidiasis. For example, OPC occurs in patients with autoimmune 
polyendocrine syndrome type 1 (APS-1), a congenital autoimmune syndrome caused by mutations 
in AIRE and characterized by circulating auto-antibodies that neutralize not only IL-17A and IL-
17F but also IL-22 [106-108, 229]. Mice with IL-22 impairments (via gene deficiency or antibody 
neutralization) are susceptible to OPC [74, 230, 231], and reduced IL-22 expression is associated 
with human chronic mucocutaneous candidiasis (CMC) [232]. Nonetheless, relatively little is 
known about the mechanisms of antifungal immunity mediated by IL-22 in this setting or in other 
oral diseases. 
The oral mucosa provides a vital physical barrier to limit pathogen invasion, yet 
mechanisms of oral mucosal immunity remain surprisingly under-studied, especially compared to 
other mucosal tissues such as the lung or gut. The oral mucosa is a stratified non-keratinizing tissue 
composed of distinct epithelial layers [80, 233]. A proliferative basal epithelial layer (BEL) 
undergoes a program of differentiation that gives rise to the post-mitotic suprabasal epithelial layer 
(SEL). This differentiation process maintains the tissue and restores barrier immunity after 
infection or injury [80, 82, 234]. Each layer is characterized by expression of specific pairs of 
cytokeratin filaments. Like most stratified epithelia, BEL expresses keratins-5 and -14 (K14, K5). 
However, the SEL expresses K4 and K13, which have a more restricted expression pattern. IL-
17R signaling activity is generally restricted to non-hematopoietic cells [235, 236], and we 
previously demonstrated that IL-17RA in K13+ SEL cells is essential for immunity to OPC [237]. 
Similar to the IL-17R, the IL-22 receptor is expressed mainly in non-hematopoietic cells and is 
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implicated in gastric C. albicans infections [238], yet remarkably little is known about IL-22 
signaling and function in the oral mucosa.  
In this chapter, I show that IL-22 functions non-redundantly with IL-17 to limit oral fungal 
infection. Although expression kinetics are similar between these cytokines, there were unexpected 
differences in cellular sources, downstream target gene expression and the nature and localization 
of the essential cytokine-responsive cells within the stratified oral epithelium. IL-22 induces 
proliferation and survival of BEL cells. Moreover, IL-22-dependent signals are required for 
renewing the IL-17-responsive SEL. Hence, IL-22/IL-22RA1 signaling ‘licenses’ the oral IL-17 
signaling response, despite acting in a distinct epithelial layer.  
3.2 Results 
3.2.1 IL-22 protects against OPC 
To compare the roles of IL-22 and IL-17 in OPC, we tracked the time course of Il22 and 
Il17a mRNA expression in the oral mucosa (tongue) of wild-type (WT) mice following sublingual 
C. albicans infection [86, 239].  Il22 and Il17a transcripts were not detectable at baseline but were 
induced contemporaneously at ~16-24 h post-infection (p.i.). Expression of both peaked at 48 h 
and returned to undetectable levels by 96 h (Figure 3.1A-B). Similar to our previous report, Il22-
/- mice were susceptible to OPC, with fungal loads consistently averaging ~103 CFU/g of tongue 
tissue at 5 days p.i., whereas WT mice fully cleared the infection by this time point (Figure 3.1C) 
[74]. Fungal loads in Il22-/- mice were typically ~1/2 log lower than in mice with IL-17 signaling 
defects (Il17ra-/- or Act1-/-), also consistent with prior findings (Figure 3.1C) [74, 240, 241].  
 42 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: IL-22 is protective against OPC 
The indicated mice were sublingually inoculated with cotton ball-saturated PBS (Sham) or 
C. albicans (OPC). Each symbol represents 1 mouse.  Total mRNA from tongue homogenates of 
infected WT mice was subjected to qPCR for Il22 (A) and Il17a (B) and normalized to Gapdh at 
each time point. Graphs show mean + SEM. Data are pooled from 4-9 mice per group. (C) Fungal 
burdens were determined by CFU enumeration on YPD/Amp agar at day 5 p.i. Graphs show 
geometric mean + SD. Data were pooled from 3 independent experiments. Dashed line indicates 
limit of detection (~30 CFU/g). Data were analyzed by ANOVA or Student’s t-test, with Mann-
Whitney correction for fungal load analysis. **p<.01, ****p<.0001. 
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3.2.2 IL-22 is non-redundant with IL-17 receptor signaling in protecting against OPC 
We next evaluated the impact of IL-22 on antifungal events in OPC. Since neutrophils are 
important in antifungal immunity, we assessed neutrophil recruitment by flowcytometry using 
tongue single cell suspensions. In line with previous data, Il17ra-/- mice exhibited impaired 
neutrophil recruitment to the tongue, measured at day 2 p.i. [74]. Unexpectedly, Il22-/- mice 
showed increased oral neutrophil frequencies and numbers (Fig. 3.2A, B), despite there being no 
differences in fungal load compared to Il17ra-/- mice at this time point (Fig. 3.2 C). Il17a and Il17f 
mRNA were elevated in Il22-/- mice (Fig. 3.2 D, E), which may explain this observation. While 
IL-22 mostly exerts anti-inflammatory properties, IL-17A and IL-17F tend to be proinflammatory 
and promote unrestricted neutrophil recruitment. Neutrophil recruitment to the site of infection is 
a two-edged sword which must be exquisitely fine-tuned. Failure to modulate neutrophil 
recruitment can promote neutrophil mediated damage to the epithelium. In line with this, a 
previous study with bleomycin-induced acute lung injury model, showed that IL-22 was only  
 
Because mice are naïve to C. albicans, the IL-17 produced during a first encounter derives 
from innate immune cells [86, 241-244]. We previously showed that antigen-independent 
CD4+TCRαβ+ cells that express IL-17 (‘natural’ Th17 cells, nTh17) are required for effective 
immunity to OPC [37, 86, 245, 246]. These nTh17 cells undergo proliferative expansion during 
the first two days of C. albicans infection in an IL-1R-dependent manner [37, 86, 136]. We 
therefore sought to determine whether IL-22 contributes to proliferation of nTh17 cells. In Il22-/- 
mice, the frequencies of proliferating (Ki67+) CD4+TCR+ cells were comparable to WT mice 
following infection (Fig. 3.2F), indicating that IL-22 does not regulate nTh17 proliferation.  
In view of the many similar functions ascribed to IL-22 and IL-17 at mucosal surfaces 
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[202], we asked whether IL-22 acts redundantly with IL-17 in OPC. Treatment with neutralizing 
Abs against IL-22 in Act1-/- mice (which are fully impaired for IL-17R signaling [247] resulted in 
higher fungal burdens than isotype-treated controls (Fig. 3.3 A). Similarly, blocking IL-17A in 
Il22-/- mice led to significantly higher fungal burdens compared to isotype-treated controls (Fig. 
3.3B). Weight loss was more pronounced in mice lacking IL-22 than in WT mice, but addition of 
anti-IL-17A Abs did not cause further weight loss (Fig. 3.3C). Thus, IL-22 and IL-17 act 
cooperatively but non-redundantly to control OPC. 
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Figure 3.2: IL-22 modulates neutrophil recruitment but not nTh17 proliferation 
(A) Tongue homogenates were prepared on day 2 p.i. Left: A representative FACS plot showing 
percent of CD11b+Ly6G+ neutrophils (gated on live, CD45+ cells). Right: Data from 3 independent 
experiments. (B) FACS plot showing neutrophil numbers from one experiment (C) The indicated 
mice were subjected to OPC and fungal burdens were assessed at day 2 p.i.. (D-E). Il17a and Il17f 
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in total tongue RNA was assessed by qPCR relative to Gapdh on day 2 p.i.. Graphs show mean + 
SEM relative to Sham-infected WT mice. (F) WT and Il22-/- mice were orally challenged with C. 
albicans or PBS. Tongue homogenates were prepared at day 2 p.i. and lymphocytes separated by 
percol gradient centrifugation. Cells were gated on live lymphocytes. Representative FACS plot 
of proliferating CD45+TCRB+CD4+ (left) and summary plot (right) are shown.  
 
Figure 3.3: IL-22 is non-redundant with IL-17 signaling in oral antifungal immunity 
(A) Mice were injected i.p. with anti-IL-22 or isotype control IgG (150ug) on days -1, 0, 1, 2, and 
3 relative to infection. CFU was assessed on day 4, pooled from 2 independent experiments. (B). 
Mice were treated with anti-IL-17A or isotype control (IgG2a) (200 ug) injected i.p. on days -1, 1, 
and 3 relative to infection. CFU was assessed on day 5, pooled from 3 independent experiments. 
(C) Weight loss was assessed daily and shown relative to day 0. Data were analyzed by ANOVA 
or Student’s t-test, with Mann-Whitney correction for fungal load analysis. *p<.05, **p<.01, 
***p<.001, ****p<.0001. 
3.2.3 Determining induction requirements for IL-22 during OPC 
Conventional adaptive Th17 responses to C. albicans are triggered by sensing of -glucans 
in the fungal cell wall via the Dectin-1/CARD9 signaling, which induces Th17-polarizing 
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cytokines (IL-23 and IL-6) [51, 116, 129, 248-251]. Here, we assessed the essential triggers of IL-
22 in innate responses to OPC. IL-23 maintains effector Th17 functions and it is implicated as a 
critical driver of IL-22 expression in many settings [97, 146, 159, 161, 163]. As expected, Il23r-/- 
mice showed impaired oral Il22 expression following C. albicans infection (Fig. 3.4A), consistent 
with elevated fungal loads seen in Il23r-/- mice [74]. However, mice lacking Dectin-1 (Clec7a−/−) 
or CARD9 (Card9-/-) (which are important for -glucan recognition and signaling downstream of 
C-type lectin receptors respectively) induced Il22 mRNA normally (Fig. 3.4A). In some settings, 
IL-22 is induced in Th17 cells by the aryl hydrocarbon receptor (AhR) or serum amyloid A (SAA) 
[252, 253]. However, Ahr-/- mice did not exhibit any obvious deficit in Il22 induction and were 
resistant to OPC (Fig. 3.4B, C). Similarly, SAA1/2-deficient mice were resistant to OPC and Il17a, 
Il17f and Il22 were induced normally in the oral mucosa (Fig. 3.4D, E).  
Since these prototypical IL-22-inducing signals were dispensable for acute IL-22 
induction, we next evaluated the role of candidalysin, a recently described trigger of anti-Candida 
immunity. This fungal cytolytic peptide, encoded by the ECE1 gene, is produced only by hyphae 
and is needed for optimal expression of IL-17 and proliferation of nTh17 cells after oral 
C. albicans challenge [34, 37]. WT mice were infected with ECE1-deficient (ece1Δ/Δ), 
candidalysin-deficient (Clys/), or an ECE1 re-complemented strain (Rev). Infection with 
ece1Δ/Δ or Clys/ caused reduced Il22 mRNA expression compared to Rev (Fig. 3.4F). IL-22 
protein levels were similarly affected, assessed using IL22TdTomato reporter mice [Shen et al., 
2015] (Fig. 3.4G). Notably, these strains showed similar fungal burdens at this time point (Fig. 
3.4H). Thus, IL-23 and candidalysin but not Dectin-1/CARD9, AhR or SAA1/2 are required for 
innate IL-22 production during OPC. 
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3.2.4 γδ-T cells and nTh17 cells are the predominant sources of IL-22 during OPC 
We next delineated the oral cellular sources of IL-22 during OPC. As expected, chimeric 
mice that received Il22-/- bone marrow (BM) developed OPC, regardless of recipient genotype, 
indicating that IL-22 in hematopoietic cells is required for C. albicans clearance (Fig. 3.5A). We 
then analyzed tongue tissue from IL22TdTomato reporter mice at day 2 p.i., the time point when 
Il22 mRNA expression peaks (Fig 3.1A). There were almost no detectable CD45+TdTomato+ cells 
prior to infection, indicating that IL-22 is not expressed in the oral mucosa at baseline. After 
infection however, a substantial population of reporter-positive cells was present (Fig. 3.5B). Of 
these, γδ-T cells constituted the dominant TdTomato+ population (58%), followed by 
CD4+TCRαβ+ cells (26%). A population of CD4-TCR+ cells (8%) and TCR-negative cells (8%) 
also expressed the reporter (Fig 3.5B). This expression pattern contrasts to some extent with that 
of IL-17, based on prior studies using an IL-17A fate tracking reporter mouse [37, 86, 254] 
(Fig 3.5C). 
 49 
 
Figure 3.4: Determinants of IL-22 induction in acute OPC 
The indicated mice were subjected to OPC. Each symbol represents 1 mouse (A) Tongues were 
harvested on day 2 p.i. and Il22 mRNA was assessed by qPCR, normalized to Gapdh. Graphs 
show mean + SEM relative to sham-infected WT mice. (B-C) The indicated mice were subjected 
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to OPC. Fungal burdens were assessed at day 5 p.i. (B) and Il22 mRNA was assessed by qPCR 
normalized to Gapdh (C). Data is from one experiment. (D-E) The indicated mice were subjected 
to OPC. Fungal burdens were assessed at day 5 p.i. (D) and Il22, Il17a and Il17f mRNA were 
assessed by qPCR normalized to Gapdh at day 2 p.i. (E). Data is pooled from one to two 
experiments. (F-H) WT or Il22TdTomato mice were infected with the indicated C. albicans 
strains. Tongue Il22 mRNA was assessed by qPCR on day 2 p.i. normalized to Gapdh (F). Data 
were pooled from 2 independent experiments. Tongue homogenates were prepared 2 days p.i. 
Cells were gated on the live CD45+TdTomato+ population. (G) Representative FACS plot is shown 
above. Summary graphs are shown below. Data are representative of 2 experiments. Each dot 
represents cells pooled from 2 mice tongues. (H) Fungal burdens were assessed at day 5 p.i.. Data 
was analyzed by T test, and ANOVA. *p<.05, **p<.01, ***p<.001, ****p<.0001 
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Figure 3.5: Cellular sources of IL-22 during OPC 
(A) BM from the indicated donors was transferred into irradiated recipients. After 6-9 weeks, 
chimeric mice were subjected to OPC and fungal burdens assessed on day 5 p.i. Data were pooled 
from 2 experiments. (B)  On day 2 p.i., tongue homogenates from Il22TdTomato mice were stained 
for the TCR and TCR and gated on the live CD45+TdTomato+ population. Left: representative 
FACS plots. Right: Pooled results from 3 independent experiments. Each symbol represents data 
from 2 pooled tongues. (C) Comparisons of the relative percentages of IL-22+ cells (left) or IL-
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17+ cells [data from [37]] isolated from tongues of mice 2 days p.i. and analyzed by flow 
cytometry. Data were analyzed by ANOVA or Student’s t-test, with Mann-Whitney correction for 
fungal load analysis. **p<.01, ***p<.001, ****p<.0001 
3.2.5 Non-hematopoietic cells are the major responders to IL-22 during OPC  
IL-22 signals through a heterodimeric receptor complex composed of IL-22RA1 and IL-
10R2. While IL-22RA1 is mainly found in non-hematopoietic cells, IL-10R2 is more broadly 
expressed. IL-22RA1 is also shared with other IL-10 family cytokines beside IL-22 [255]. We 
sought to compare the susceptibility of Il22-/- mice and Il22ra1-/- mice to OPC. Il22ra1-/- mice 
showed a very similar, albeit not statistically identical, susceptibility to OPC compared to Il22-/- 
mice (Fig. 3.6A). The difference could be indicative of a contribution of other IL-22RA1-
dependent cytokines, though this possibility was not pursued. By 14 days p.i., most Il22ra1-/- mice 
had cleared the infection (Fig. 3.6B), which contrasts with Il17ra-/- mice that were previously 
shown to maintain oral fungal loads as long as 17 days p.i. [74, 88]. Contrary to the predominant 
role of IL-22RA1 in non-hematopoietic cells, some recent studies show the expression of IL-
22RA1 in macrophages during tuberculosis and pneumonia infections in the lungs [180, 181]. To 
identify cell compartments requiring IL-22RA1 in OPC, we created reciprocal BM chimeras with 
WT and Il22ra1-/- mice. Regardless of BM source, WT recipients were resistant to OPC, whereas 
irradiated Il22ra1-/- recipients failed to clear C. albicans (Fig. 3.6C). Thus, IL-22RA1-mediated 
signaling in non-hematopoietic cells is required for effective oral antifungal immunity. 
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Figure 3.6: IL-22RA1 in non-hematopoietic cells is indispensable for protection against 
OPC 
The indicated mice were subjected to OPC. (A) Fungal burdens were assessed on day 5 p.i.. Bars 
show geometric mean + SD. Data were pooled from 2 experiments. (B) Il22ra1fl/fl and Il22ra1-/- 
mice were subjected to OPC. Fungal burdens were assessed at days 5, 7, 10 and 14 p.i.. Bars show 
geometric mean + SD. Data were pooled from 1-2 experiments (C) BM from indicated donors was 
transferred into irradiated recipients. After 6-9 weeks, mice were subjected to OPC and fungal 
burdens assessed on day 5 p.i.. Data were pooled from 2 experiments and analyzed by ANOVA or 
Student’s t-test, with Mann-Whitney correction. **p<0.01, ***p<0.001, ****p<0.0001 
3.2.6 IL-22 signaling in the oral basal epithelium is required for protection against OPC  
In view of the observed predominant role of IL-22RA1 in non-hematopoietic cells, we 
sought to determine more precisely where IL-22RA1 was expressed and functional in the tongue 
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during OPC. Oral epithelial tissue is characterized by morphologically distinct expression of 
cytokeratins. Keratin 13 (K13) is expressed in differentiating SEL cells in the post-mitotic, 
terminally differentiated layer, which overlays the proliferative keratin14 (K14) expressing BEL 
[80]. Consequently, K13+ epithelial cells make first contact with C. albicans during hyphal 
invasion and are highly subject to fungal-induced tissue damage. Moreover, this SEL layer is then 
sloughed and swallowed as part of the antimicrobial clearance response [3]. The SEL is 
replenished by proliferation of the underlying basal K14+ cells which have stem-like properties, 
but how this is controlled in OPC is unclear. Immunofluorescent (IF) staining indicated that IL-
22RA1 was prominent in the K14+ BEL, with some staining in K13+ SEL and papillae (Fig. 3.7A). 
Isotype controls verified Ab specificity (Fig. 3.7B-C).  
To define the relative contributions of IL-22RA1 in oral epithelial cell subtypes, Il22ra1fl/fl 
mice were crossed to K13Cre or K14CreERT2 mice [88, 256]. Conditional deletion of Il22ra1 in SEL 
was efficient, as verified by IF. While the loss of IL-22RA1 staining was evident in the SEL, IL-
22RA1 staining was still present in the BEL (Fig. 3.8A). Il22ra1K13 mice were resistant to OPC 
(mean fungal load ~19), indicating that IL-22 signaling in SEL is dispensable for fungal control 
(Fig. 3.8B). Remarkably, these results show that IL-22 signals in a spatially distinct manner from 
IL-17, because deletion of Il17ra in K13+ cells resulted in significant susceptibility to OPC [88]. 
To delete IL-22RA1 in BEL, Il22ra1K14ERT2 mice and controls (Il22ra1fl/fl, Il22ra1fl/-K14ERT2, 
Il22ra1K14ERT2) were administered tamoxifen for 5 days before they were infected with C. albicans. 
Inducible deletion of IL-22RA1 was efficient in some mice as evidenced by almost complete loss 
of IL-22RA1 in the BEL (Fig. 3.8C) while others had patchy deletion of IL-22RA1. In contrast to 
Il22ra1K13 mice, loss of Il22ra1 in K14+ cells led to markedly increased susceptibility to OPC 
(fungal load ~508), demonstrating that IL-22R signaling is commensurate with its expression 
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profile in the BEL (Fig. 3.8D).  
Hepatic IL-22R was previously shown to be needed for pulmonary bacterial immunity 
[221], so we subjected mice with a liver-specific deletion of IL-22RA1 (Il22ra1Alb) to OPC. As 
shown, they were resistant to OPC (Fig. 3.8E). Hence, these data show that IL-22RA1 signaling 
in the K14+BEL, but not the K13+SEL, is required for oral fungal control, and accordingly that IL-
17 and IL-22 function in different epithelial compartments.  
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Figure 3.7: IL-22RA1 is expressed in the oral suprabasal and basal epithelial layers 
Frozen sections from WT tongues were co-stained with DAPI and Abs against (A) K13, K14, IL-
22RA1and (B) isotype controls. Suprabasal and basal epithelial layers are indicated. Images are 
representative of a minimum of 3 sections. Size bar = 200 µM  
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Figure 3.8: IL-22 signaling in the basal epithelial layer is required to control OPC 
(A and C) IF staining of IL-22RA1 in tongue sections from the indicated mice. Size bar = 200 µM. 
(B, D and E) Fungal burdens were assessed on day 5 p.i. in the indicated mice. In (D), all except 
Il22-/- mice were administered tamoxifen for 5 days prior to OPC. Bars show geometric mean + 
SD. Data were pooled from 3 experiments for (B and D) and one experiment for E. Data were 
analyzed by ANOVA with Mann-Whitney correction. **p<.01, ****p<.0001. 
Il2
2ra
1
fl/f
l
Il2
2ra
1
K1
3
Il2
2ra
1
-/-
104
103
102
101
100
C
F
U
/g
 o
f 
to
n
g
u
e
****
Il22ra1K13
Il22ra1fl/fl
MergeIL-22RA1DAPI
104
103
102
Il22
ra1
fl/fl
101
100
Il22
-/-
C
F
U
/g
 o
f 
to
n
g
u
e
Il22
ra1
fl/-
K1
4E
R
T2
Il22
ra1
K1
4E
R
T2
**
****
Il22ra1K14ERT2
Il22ra1fl/fl
MergeIL-22RA1DAPI
 A 
 C 
 B 
 D 
C
F
U
/g
 o
f 
to
n
g
u
e
                    
****
104
103
102
101
100
Il2
2ra
1
fl/f
l
Il2
2ra
1
-/-
Il2
2ra
1A
lb
 E 
 58 
3.2.7 IL-22 promotes BEL proliferation and survival during OPC 
To determine the mechanisms by which IL-22 promotes immunity during OPC and 
whether this differs from IL-17-driven responses, we evaluated RNASeq profiles of total tongue 
mRNA from C. albicans-infected Il22-/-, II17ra-/- and WT mice. As shown, there was differential 
expression of genes in Il22-/-, II17ra-/- and WT mice (Fig 3.9A). In keeping with the observation 
that IL-17 and IL-22 act non-redundantly, there were distinct gene sets induced by IL-22 (368 
genes) versus IL-17RA (931 genes). There were also many overlapping genes controlled by both 
cytokines (215 genes) (Fig. 3.9B).  
GSEA revealed increased expression of mitotic spindle checkpoint genes in WT versus 
Il22-/- mice (Fig. 3.10A), normalized enrichment score (NES) 1.4 (P<0.01). Specifically, positive 
cell cycle regulatory genes (Stat3, Jun, Sphk1) were reduced and negative regulators of cell cycle 
(Cdkn1c, Ddit3, Ets1) were elevated (Fig. 3.10B). Concordantly, Il22ra1-/- mice showed decreased 
IF staining of Ki67 in K14+ cells following C. albicans infection, indicating that IL-22 is a major 
driver of BEL proliferation (Fig. 3.10C). Consistently, there was a trend to decreased 
bromodeoxyuridine (BrdU) incorporation in Il22-/- K14+ BEL cells following oral C. albicans 
infection (Fig. 3.10D). We next evaluated cell cycle progression in Epcam+ epithelial cells from 
Il22-/- and WT tongues by BrdU and 7-aminoactinomycin D (7-AAD) staining. As shown, there 
were comparable proportions of cells in the Gap2/mitotic (G2/M) phase, fewer in the synthesis (S) 
phase and more in the G0/G1 phase (Fig. 3.11). GSEA also suggested enrichment of cell death-
associated and DNA damage response genes (Fig. 3.12A, Fig. 3.12B). Indeed, Il22-/- mice had 
higher frequencies of active caspase 3+ and TUNEL+ epithelial (Epcam+) cells following infection 
(Fig. 3.12 C, D, E). Hence, IL-22 promotes BEL proliferation during OPC, while limiting 
accumulation of apoptotic cells.  
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Figure 3.9: Transcriptional profile of Il22-/- and Il17ra-/- mice during OPC 
RNA-Seq was performed on tongue mRNA from WT, Il22-/- and Il17ra-/- mice, isolated 24 h p.i. 
(A) Heatmap of differentially expressed genes in WT, Il22-/- and Il17ra-/- mice (parthekflow) (B) 
Venn diagram of differentially regulated or overlapping genes in infected Il22-/- and Il17ra-/- 
compared to WT mice. 215 genes were regulated by both IL-22 and IL-17RA, whereas 368 genes 
were regulated only by IL-22, and 931 genes were regulated only by IL-17RA.  
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Figure 3.10: IL-22 drives proliferation of basal epithelial cells during OPC 
Differentially expressed genes from WT and Il22-/- mice were subjected to GSEA. (A) GSEA of 
mitotic spindle checkpoint pathway (B) Heatmap of cell cycle pathway genes (Partekflow) in WT 
or Il22-/- mice. (C) IF staining of DAPI, Ki67 and K14 in WT and Il22ra1-/- mice at 2 days p.i. 
Data are representative of images from 2 mice per group. Size bar = 100 µM. (D) BrdU was 
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administered to the indicated mice 24 h p.i., and tongues harvested on day 2 p.i.. Incorporation of 
bromodeoxyuridine (BrdU) in CD45-EPCAM+K14+ cells was assessed by flow cytometry. Left: 
representative FACS plot, right: summary plot. Data show mean + SEM and were analyzed by 
ANOVA. **p<0.01, *p<0.001. 
 
 
Figure 3.11: IL-22 promotes cell cycle progression in oral epithelial cells during OPC 
BrdU was administered 24 h p.i., and tongues harvested on day 2 p.i.. Cell cycle/apoptotic status 
of CD45-EPCAM+ cells was determined by bromodeoxyuridine (BrdU) and 7-aminoactinomycin 
(7AAD) staining. Left: representative FACS plot, right: summary plot. Data show mean + SEM 
and were analyzed by Student T test. *p<0.05, **p<0.01. 
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Figure 3.12: IL-22 promotes survival of oral epithelial cells during OPC 
Differential gene expression data from WT, Il22-/- was subjected to GSEA (A) GSEA of cell death 
pathway genes. Normalized enrichment score is shown on Y-axis (B) Heat map of cell death 
pathway genes (Partekflow) in WT and Il22-/- mice in response to OPC. (C) Frequency of CD45-
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EPCAM+ cells staining positive for active (cleaved) caspase-3 in tongue homogenates at day 2 p.i. 
measured by flow cytometry. Left: Representative FACS histogram. Right: Pooled data from 4 
independent samples. Data analyzed by student’s t-test. (D) DAPI and TUNEL staining of tongue 
sections from the indicated mice at day 2 p.i.. Images are representative of sections from 4 mice 
per group. Size bar = 200 µM (E). Quantification of TUNEL+ cells from panel D. Data analyzed 
by student T test, ANOVA and post-hoc Tukey’s test. **p<0.01, ***p<0.001, ****p<0.0001. 
3.2.8 IL-22 restores IL-17R expression and signaling in SEL to sustain antifungal immunity 
in OPC 
In stratified epithelia such as the oral mucosa, proliferating BEL regenerate the post-mitotic 
SEL [80, 82]. In view of the impaired proliferation of basal epithelial cells observed in Il22-/- mice 
(Fig. 3.10C), I investigated how this defect impacts the oral epithelium. Consistently, genes 
implicated in tissue repair, keratinization and epithelial differentiation were impaired in Il22-/- mice 
compared to WT mice (Fig. 3.13A). Though IL-17RA signaling in K13+ SEL cells is critical for 
immunity to OPC [88], the factors that restore the SEL after sloughing have not been well defined. 
In view of the observed role of IL-22 on the BEL, I hypothesized that IL-22 might indirectly impact 
IL-17 signaling in OPC by restoring the IL-17RA-expressing SEL. Indeed, transcriptomic data 
and qPCR revealed that there was decreased Il17ra mRNA expression in Il22-/- tongue (Fig. 3.13B, 
C). IF staining revealed loss of IL-17RA in the SEL of WT mice after C. albicans infection, which 
was even more pronounced in Il22-/- mice (Fig. 3.13D). Flow cytometry also demonstrated that IL-
17RA cell surface expression was reduced in WT and Il22-/- CD45-Epcam+ oral epithelial cells 
following C. albicans infection, though the difference between WT and Il22-/- mice was modest 
(Fig. 3.13E). Consistent with reduced IL-17RA in oral epithelium, canonical IL-17 target genes 
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associated with immunity to C. albicans were downregulated in Il22-/- mice during OPC, including 
the essential antimicrobial peptide -defensin-3 (Defb3) (Fig 3.13F). Collectively, these data 
support a model in which IL-22 signaling promotes BEL-intrinsic signals that mediate anti-
Candida immunity. Accordingly, IL-22 ‘licenses’ IL-17R signaling by renewing the SEL and 
thereby restoring the capacity of the tissue to respond to IL-17R, which is vital in controlling OPC 
(Fig. 3.14).  
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Figure 3.13: IL-22 promotes survival of oral epithelial cells during OPC 
(A) Heatmap of genes implicated in tissue repair, wound healing, keratinization and epithelial 
differentiation. (B) Heatmap of IL-17 signature genes in OPC. (C) qPCR of Il17ra expression 
normalized to Gapdh in tongue tissue from the indicated mice subjected to OPC and analyzed on 
day 2 p.i.. Data show mean + SEM relative to sham-infected mice. Data analyzed by ANOVA or 
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student’s t-test. (D) IF staining of IL-17RA and DAPI in the indicated mice on day 2 p.i. Size bar 
= 200 µM (E) IL-17RA expression in CD45-Epcam+ oral epithelial cells in WT or Il22-/- mice 
during OPC. Left: representative FACS histogram. Right: Pooled data from 2 independent 
experiments. (F) Expression of BD3 (Defb3) mRNA in tongue from WT or Il22-/- mice during 
OPC, normalized to Gapdh. Data analyzed by ANOVA or student’s t-test. *p<0.05, **p<0.01, 
***p<0.001,  
 
 
Figure 3.14: Model diagram depicting C. albicans encounter with the stratified oral 
epithelium 
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Fungal hyphae induce cellular damage and secrete the peptide candidalysin, which facilitates tissue 
invasion and activates innate IL-17- and IL-22-producing lymphocytes (see Refs [34, 37]. IL-17 
was shown previously to act dominantly on K13+ cells of the suprabasal epithelial layer (SEL) 
[88]. In contrast, IL-22/STAT3 promotes proliferation of the K14+ basal epithelial layer (BEL) 
that serves to restore the IL-17R-expressing SEL, thus maintaining IL-17-induced antifungal 
signals such as -defensins and neutrophil responses that are required to mediate clearance of C. 
albicans. Diagram created on Biorender.com. 
3.3 Discussion 
Although IL-22 and IL-17 are both produced by Type 17 cells, these cytokines are distinct 
in structure, receptors, and downstream signaling pathways [202]. Even so, they are usually viewed 
interchangeably in the context of mucosal immunity. The protective function of IL-22 in oral 
candidiasis has been recognized for some time, yet its mechanisms of action are incompletely 
understood. In non-oral manifestations of C. albicans infection or colonization (systemic, vaginal, 
dermal or gastric), IL-22 plays surprisingly different roles, emphasizing that specific cytokine 
responses even to the same pathogen are influenced by tissue milieu [74, 238, 257-260].  
While multiple families of CMC patients have been identified with mutations in IL-17R 
pathway genes [109, 261, 262], thus far no humans with genetic IL-22-deficiencies have been 
reported. Nonetheless, it does not necessarily follow that this cytokine is unimportant in humans, 
only that its contribution to host defense is more modest than that of IL-17. This would be 
analogous to the role of IL-17F. In mice, loss of IL-17F alone does not cause OPC, yet dual 
blockade of IL-17F and IL-17A significantly increases susceptibility [241, 247]. In humans, a 
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family with IL-17F mutations has been described with CMC, suggesting a role in mucosal 
candidiasis [109]. AIRE-deficient humans have circulating neutralizing Abs against IL-17F, IL-22 
and IL-17A, thought to help explain the CMC manifestations in these patients [100, 106-108]. In 
most mammals, though not mice, Th17 cells also express IL-26, a member of the same cytokine 
family as IL-22, and this cytokine may also be a target of biologic therapy [263]; however, there 
is no evidence for autoantibodies against IL-26 in AIRE deficiency nor are IL-26-deficient humans 
described [264]. 
 The mechanisms by which IL-17 and IL-22 act in OPC are divergent [202]. Whereas loss 
of IL-17 impairs neutrophil recruitment [74, 88], IL-22 deficiency led to increased neutrophil 
tissue infiltration, presumably because Il17a is concomitantly elevated. These opposing activities 
on the neutrophil response may help to restrain excessive inflammation. Interestingly, the capacity 
of IL-17 to drive oral neutrophil recruitment in OPC is not observed by all who use this OPC model 
[129, 136], possibly reflecting altered microbiota or other distinctions among animal facilities. 
Hence, the events controlling oral mucosal immunity are complex and dynamic. 
The immunology of the oral cavity is less well understood than other mucosae [3, 234]. In 
part, this is due to technical challenges associated with isolating cells from oral mucosal sites and 
the paucity of tools available to interrogate cell types within this tissue [242]. We show here that 
IL-22 and IL-17 are produced by and function in distinct oral cell subtypes in the setting of OPC. 
Unlike humans, mice do not harbor C. albicans as a commensal organism, and hence acute oral 
infection with C. albicans reflects an innate, not adaptive, immune response. In prior studies, IL-
17 was shown to be produced by several innate lymphocyte subsets, including TCR+ ‘natural’ 
Th17 cells (nTh17), which express CD4, have a diverse TCR repertoire, and are activated in a non-
antigen-specific manner [37, 86]. IL-17 is also detected to a lesser extent in γδ-T cells and, in some 
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reports, ILC3 cells [37, 86, 241]. Upon a recall encounter to C. albicans, mice generate 
conventional, antigen-specific Th17 cells that additionally contribute to the IL-17-producing pool, 
where they augment immunity to C. albicans [53, 243, 244]. C. albicans-specific Th17 cells are 
abundant in humans, as C. albicans is encountered very early in life. Moreover, C. albicans-
specific Th17 cells recognize and provide cross-reactive protection against other fungal species, 
which is likely why maintaining C. albicans as a commensal is evolutionarily advantageous [151, 
265-267].   
We observed that γδ-T cells were the predominant oral source of IL-22 during OPC, 
followed by nTh17 cells and TCR-negative cell types. These results parallel observations made in 
skin upon C. albicans infection, where -T cells are the major source of Type 17 cytokines. [116]. 
Since the sources of these cytokines were made using reporter mice which may under-report, 
defining the relative differences in sources of IL-17 and IL-22 is worth pursuing in more detail 
[254, 268]. Nonetheless, the induction requirements for IL-22 during OPC are remarkably similar 
to that of IL-17; namely, IL-23 and the fungal peptide candidalysin are crucial, whereas classical 
fungal PRRs such as Dectin-1, CARD9 or activators of conventional Th17 cells such as AhR or 
SAA1/2 are dispensable [37, 53, 252, 253]. The finding that AhR was not essential to induce IL-
22 or clear C. albicans from the mouth, although initially unexpected, is consistent with 
observations that AhR facilitates EGFR phosphorylation in OPC, a key step in fungal adhesion, 
endocytosis and invasion in OECs [23, 24, 36, 58].  
IL-17 and IL-22 are typically depicted signaling on the same cell types to mediate mucosal 
immunity, which is the case in non-stratified epithelia such as gut or lung [159, 202]. Hence, we 
did not anticipate that IL-17 and IL-22 would act upon spatially distinct cell types in the oral 
mucosa. To show this, we made use of a mouse that expresses Cre under control of the murine 
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Krt13 proximal promoter, one of the first tools allowing relatively specific deletion in the oral 
mucosa [88]. The K13Cre mouse deletes conditionally in the SEL of the tongue, buccal mucosa, 
esophagus and vaginal tract, with no detectable Cre activity in BEL of any tissue examined. Using 
this system, we found that IL-17RA acts dominantly within K13+ cells in the setting of OPC, with 
fungal burdens only slightly reduced compared to a full Il17ra-/- animal [88]. In contrast, deletion 
of IL-22RA1 in K13+ SEL did not impact fungal clearance during OPC. GSEA of RNASeq data 
predicted a role for IL-22 in tissue proliferation and repair during C. albicans infection. Indeed, 
IL-22/IL-22R signaling was vital for proliferation and survival of the K14+BEL, consequently 
replenishing the SEL. Thus, IL-22 indirectly permits essential IL-17-driven antifungal events to 
occur by restoring the post-mitotic superficial layer where IL-17RA is expressed. This spatial 
stratification of the IL-22R versus the IL-17R enforces the specificity, diversification, and 
integration of cues that ensure oral epithelial integrity, restrain undue inflammation and promote 
antifungal immunity. 
The oral mucosa is among the most resilient epithelial surfaces [75]. By virtue of their 
location, superficial K13+ OECs are the first to make contact with C. albicans. In its non-invasive 
yeast (commensal) form, C. albicans causes no damage to the SEL, which was recently shown to 
be due to the fact that this form of the fungus does not produce the pore-forming virulence factor 
candidalysin [34]. Accordingly, there is insufficient expression of IL-1 or other DAMPs that would 
activate innate lymphocytes to produce IL-17 or IL-22. This creates an environment where benign 
commensal C. albicans colonization is favored. However, in conditions that are conducive to 
hypha formation and invasion into tissue, a different scenario ensues. As part of the response to 
fungal invasion, the damaged SEL is sloughed and swallowed, which helps to clear C. albicans. 
The resulting epithelial cell damage also triggers production of IL-1 and IL-36, which promote IL-
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17 and IL-23 expression, respectively [37, 117, 135, 136]. IL-17R signaling in the SEL upregulates 
chemokines that recruit neutrophils as well as -defensins that exert direct antifungal activity [74, 
88, 131, 269]. Hyphal invasion thus establishes an inflammatory milieu that is initiated by 
candidalysin-induced SEL damage, potentiated by IL-17- and candidalysin-induced effectors such 
as IL-1 and IL-36, and ultimately resolved upon clearance of the pathogen [37, 135].  
IL-22 acts in many epithelial surfaces. Events in the oral epithelia are reminiscent of skin, 
where K14+ stem cells resupply superficial epithelial cells to maintain barrier integrity [81, 82]. 
The skin also possesses ‘memory’ properties that accelerate tissue repair after future insults, 
though whether this occurs in the mouth is unknown [270]. IL-22RA1+ epithelial cells in colonic 
epithelium maintain genome integrity and limit apoptotic cell accumulation during genotoxic 
stress [216]. Similarly, IL-22 signaling in the BEL during OPC promotes replacement of damaged 
epithelial cells, prevents accumulation of inflammatory apoptotic cells, preserves genome integrity 
and, as shown here, helps maintain IL-17-driven antifungal activities.  
IL-22 maintains the intestinal epithelial barrier during intestinal colonization of C. albicans 
[196, 238]. Unlike the mouth, IL-17 is not protective in gut but rather promotes a tissue-destructive 
inflammatory cycle in response to C. albicans colonization [238]. In fact, IL-17 signaling in gut is 
generally more reparative than inflammatory [271-275], which is thought to explain why anti-IL-
17 biologic therapies failed in trials of Crohn’s disease [276]. Anti-IL-17 biologics are associated 
with low but statistically significant rates of OPC, though it is rare for patients to stop therapy for 
this reason [277]. Anti-IL-22 antibodies are under evaluation for skin pathologies such as atopic 
dermatitis [278], but rates of C. albicans infections have not been reported. Our data predict that 
combinations of anti-IL-17 and anti-IL-22 could result in more severe mucosal candidiasis 
infections than either therapy alone. 
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In summary, these results reveal a deeper understanding of the antimicrobial defense 
functions of oral epithelial cells and a complex interplay between distinct cytokines of the Type17 
axis. It is clear that cells within the oral epithelium are not simply physical barriers but are 
topographically structured sentinels that work in concert to dictate the outcome of oral C. albicans 
colonization, the most common fungal infection of humans [99, 279].   
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4.0 Oral Epithelial STAT3 Signaling is Required for Oral Antifungal Immunity 
4.1 Background 
Recent studies are changing the view of the role of epithelial cells in dictating the outcome 
of immune responses at mucosal sites. Beside triggering antimicrobial peptide responses, epithelial 
cells actively serve as “crosstalk platforms” to relay cues from infecting pathogens and other 
pathological insults to the immune system. In the gut, intestinal epithelial cell interactions with the 
microbiome modulate local and systemic immune responses. Segmented filamentous bacteria 
(SFB) has emerged as one of the key commensals driving intestinal Th17 responses. During SFB 
colonization, IL-22/STAT3 dependent activation of serum amyloids (SAA1/SAA2) promotes 
Th17 differentiation and IL-17 production [252]. Oral epithelial damage induced by the C. 
albicans toxin candidalysin triggers the expansion of innate-acting CD4 T cells through IL-1 
receptor mediated signaling [37]. Thus, the cytokine milieu in the tissue microenvironment shapes 
the subsequent immunological responses, and the mucosa is central to instigating these responses. 
Cytokines including IL-1, IL-36, IL-23 and IL-22 released in response to Candida 
infection are all capable of activating STAT3 [280-284]. Indeed, many studies show that various 
cytokine activities converge on STAT3 and NF-B activation [285-287]. Importantly, the role of 
epithelial/stromal STAT3 in coordinating the innate and adaptive immune response to chronic 
inflammation and cancer have been demonstrated [288, 289]. However, the role of epithelial 
STAT3 in oral antifungal immunity is not well understood.  
Evidence for a key role of STAT3 in antifungal immunity came from Job’s syndrome/ 
autosomal-dominant hyper IgE syndrome (AD-HIES) patients who suffer from recurrent oral and 
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chronic mucocutaneous candidiasis (CMC) due to decreased Th17 generation. These patients 
harbor a dominant negative STAT3 mutation which accounts for their decreased numbers of IL-
17- and IL-22-producing Th17 cells [290, 291]. The decrease in Th17 cells is thought to be due to 
their hypo-responsiveness to Th17-inducing cytokines, namely IL-6, IL-23 and IL-21 [101, 102, 
281, 292-294]. Analogous to the STAT3 dominant negative mutations, patients with a gain of 
function mutation in STAT1 are susceptible to CMCD. The disease in these patients is attributed 
to increased STAT1-mediated signaling and a concomitant repression of STAT3 dependent 
differentiation of Th17 cells [104].  
Although these initial studies pointed to the role of STAT3 in Th17 differentiation as the 
primary cause of increased CMCD in these inherited disorders, STAT3 is a pleiotropic 
transcription factor with important roles in other cell types. Loss of STAT3 in macrophages 
promotes spontaneous colitis due to impaired anti-inflammatory response [295-297]. Similarly, 
deletion of STAT3 in the intestinal epithelium delays wound healing during colitis partly by 
regulating bacterial colonization through antimicrobial peptides and epithelial cell survival [298]. 
In contrast, STAT3 in CD4 T cells mediates disease severity in Th17-driven autoimmune 
conditions including IBD and EAE, highlighting the detrimental role of STAT3 in these contexts 
[299]. Consequently, the observed role of STAT3 is dependent on the disease context and the types 
of cells involved. In line with this, studies have demonstrated varied roles for epithelial STAT3. 
Aside from the canonical nuclear transcriptional roles of STAT3 in driving survival, proliferation, 
and maintaining stem cell like properties, non-transcriptional and metabolic roles of STAT3 in 
cellular homeostasis is beginning to emerge [184, 289].  
In this study, I investigated the role of oral epithelial STAT3 in oral antifungal immunity. 
Bioinformatic analysis of RNASeq data revealed that while STAT3 target genes/pathways were 
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down-modulated in Il22-/- mice, those genes/pathways were unexpectedly enriched in Il17ra-/- 
mice during OPC. In vivo, we demonstrated that STAT3 activation is impaired in Il22-/- mice but 
elevated in Il17ra-/- mice during OPC. We observed that phosphorylation of STAT3 was impaired 
in the BEL in Il22-/- and Il22ra1-/- mice. Consistent with this observation, mice with SEL specific 
loss of STAT3 were resistant to OPC, whereas deletion of STAT3 in the BEL resulted in increased 
susceptibility to OPC. These findings demonstrate a critical contribution of BEL STAT3 in oral 
antifungal immunity and open up new directions to critically access the likely transcriptional and 
non-transcriptional roles of STAT3 in oral antifungal immunity. 
4.2 Results 
4.2.1 STAT3 integrates IL-22 and IL-17RA transcriptional networks during OPC 
Previous transcriptomic data has shown that STAT3 activity is upregulated in the tongue 
in response to OPC in WT mice [74]. To determine how IL-22 and IL-17RA signaling impact the 
activation of STAT3, we subjected our RNASeq data (Fig. 3.9) to GSEA. Consistent with the role 
of IL-22 in STAT3 activation [228], GSEA revealed decreased enrichment in Il6/STAT3 gene sets 
(NES 1.87 p= 0.00) in Il22-/- mice compared to WT mice (Fig. 4.1A). Unexpectedly, IL-6/STAT3 
gene sets were enriched in Il17ra-/- compared to WT mice (NES 1.4, P<0.05) (Fig. 4.1B). 
Consistently, Ingenuity Pathway analysis identified STAT3 as a central upstream regulator that 
integrates the IL-22 and IL-17RA transcriptional networks (Fig. 4.1C). Within this network, 
STAT3 was connected to proliferation and apoptosis genes and transcription factors that regulate 
inflammation such as NF-B/IB (Nfkbiz) and MAPK/AP-1 (Fig. 4.1C). In line with these 
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bioinformatic predictions, IL-22 induced STAT3 phosphorylation and IB expression in TR146 
cells, a human oral epithelial cell line that has been used to understand epithelial responses to C. 
albicans [34, 37, 84] (Fig. 4.2 A, B). Together, these observations show the synergy between IL-
22 and IL-17 signaling and point to the possible role of STAT3 as a key modulator of these 
responses during OPC.  
 
 
Figure 4.1: STAT3 is a central hub linking IL-22 and IL-17RA signaling during OPC 
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RNA-Seq was performed on whole tongue mRNA from WT, Il22-/- and Il17ra-/- mice subjected to 
OPC and harvested on day 1 p.i.. (3.9A, B). GSEA of predicted IL-6/STAT3 gene sets in (A) WT 
and Il22-/- mice and (B) Il17ra-/- and Il22-/- mice from ((3.7A, B). (C). Ingenuity Pathway Analysis 
of RNA-Seq data from panel A, indicating that STAT3 is an upstream regulator integrating Il22 
and Il17ra- driven transcriptional networks.  
 
Figure 4.2: IL-22 activates STAT3, NF-B and MAPK signaling in TR146 OECs 
(A, B) TR146 OEC were stimulated with or without IL-22 (100ng/ml) for the indicated time points. 
Lysates were immunoblotted for the indicated proteins. Data are representative of two 
experiments. 
4.2.2 IL-22/IL-22RA signaling activates STAT3 in the BEL during OPC 
In view of our bioinformatic and in vitro data on STAT3, I sought to assess the state of 
STAT3 activation during OPC. While STAT3 phosphorylation was impaired in Il22-/- and Il22ra1-
/- mice (Fig. 4.3A, C), STAT3 phosphorylation was increased in Il17ra-/- mice, possibly due to 
elevated Il22 expression in these mice under these circumstances (Fig 4.3A, B). Interestingly, 
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STAT3 activation was most prominent in the BEL. These results show that, even though numerous 
stimuli have potential to activate STAT3, the dominant STAT3 response during OPC is mediated 
by IL-22RA1-dependent cytokines. Moreover, the localization of active STAT3 in the BEL but 
not SEL demonstrates the compartmentalization of responses in the oral mucosa to C. albicans 
infection. This finding also supports the idea that there is likely to be defective IL-22-driven 
signaling as part of the pathogenesis of OPC that is associated with STAT3 mutations (e.g., Job’s 
syndrome). K14 staining intensity by IF was reduced in Il22ra1-/- mice compared to Il22ra1fl/fl 
mice (Fig 4.3C). This was commensurate with RNASeq data that showed reduced Krt14 mRNA 
in Il22-/- mice (Fig. 3.9A, B), a phenomenon also observed in skin in response to C. albicans 
infections [300].  
 
 
Figure 4.3: STAT3 activation is impaired in BEL of Il22ra-/- mice during OPC 
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(A) IF staining of frozen tongue sections with DAPI and anti-pSTAT3 (Tyr705) in WT, Il22-/- and 
Il17ra-/- mice harvested 2 days p.i. . Size bar = 200 µM. (B) qPCR of Il22 induction in tongue 
harvested from WT or Il17ra-/- mice at day 2 p.i. normalized to Gapdh. (C) IF staining of DAPI, 
pSTAT3 (Tyr705) and K14 in WT or Il22ra1-/- mice at 2 days p.i.. Size bar = 200 µM. 
4.2.3 Oral BEL STAT3 is necessary for protection against OPC 
To assess the functional relevance of oral epithelial STAT3 in oral antifungal immunity, 
we generated mice with specific loss of STAT3 in the SEL and BEL using K13Cre or K14ERT2Cre 
mice respectively. While acute deletion of STAT3 in the BEL rendered mice susceptible to OPC 
(Fig. 4.4A, B), mice with germline STAT3 deletion in the SEL were resistant to OPC (Fig. 4.5). 
Together, these data demonstrate a central role and compartmentalization of STAT3 activation in 
the oral epithelium to sustain antifungal immunity.  
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Figure 4.4: STAT3 in oral BEL is indispensable for protection against OPC 
(A) All mice except Il22-/- were administered tamoxifen for 5 days, subjected to OPC and fungal 
burden assessed on day 5 p.i.. Bars show geometric mean + SD. Data was pooled from 3 
experiments. Data analyzed by ANOVA with Mann-Whitney correction. **p<0.01 (B) IF staining 
of DAPI, and pSTAT3 in the indicated mice at day 2 p.i. Size bar = 200 µM. 
 
 
Figure 4.5: Oral SEL STAT3 is dispensable for protection against OPC 
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The indicated mice were subjected to OPC and fungal burden was assessed on day 5 p.i.. Bars 
show geometric mean + SD. Data was pooled from 3 independent experiments and analyzed by 
ANOVA with Mann-Whitney correction. ****p<0.0001. 
4.3 Discussion 
Animal experimental models and ‘experiments of nature’ in humans that cause primary 
immunodeficiency syndromes have led to the identification of Th17/IL-17RA axis as a critical 
driver of antifungal immunity [74, 88, 100, 232, 301]. Impaired Th17 differentiation due to 
dominant negative mutations in STAT3 as observed in HIES patients is thought to underlie their 
increased susceptibility to oral candidiasis [101, 102]. However, STAT3 has ubiquitous functions 
in numerous cell types in different disease settings [295-299]. The oral epithelium is a major 
orchestrator of antifungal immunity [37, 88]. Nonetheless, the role of STAT3 in oral thrush 
remains underexplored. In this study, I sought to evaluate the role of oral epithelial STAT3 in 
OPC.  
Multiple cytokines and signaling pathways are known to activate STAT3 [302, 303]. Our 
GSEA data suggested that STAT3 is an integrating hub between IL-22 and IL-17 signaling 
networks (Fig. 4.1C). This finding was unexpected since IL-17RA is not known to directly activate 
STAT3. The pathways inferred from bioinformatics data (proliferation, cell cycle, and apoptosis) 
are commensurate with the known roles of IL-22 and STAT3 in epithelial proliferation and repair 
[255]. Surprisingly, IL-22/STAT3 genesets (Fig. 4.1A, B) and phosphorylation of STAT3 were 
enriched in the Il17ra-/- mice (Fig. 4.3A), even though expression of other STAT3-activating 
cytokines (e.g., IL-6 and G-CSF) were impaired in these mice. This could be due to elevated Il22 
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expression in Il17ra-/- mice (Fig. 4.3B), but likely reflects overall perturbation of the multiple 
immune response networks inferred from GSEA that may involve STAT3.   
Susceptibility to CMC in Job’s syndrome patients with STAT3 mutations is usually 
attributed to impaired STAT3-dependent Th17 differentiation [100-102]. However, in acute OPC 
in mice, STAT3 in CD4+ T cells is not required to control fungal loads [86]. Moreover CD4-/- and 
CD8-/- mice are resistant to OPC [243]. Unlike humans, mice are naïve to C. albicans and are 
unlikely to have pre-existing C. albicans specific Th17 cells. It is therefore likely that STAT3 is 
not required in Type 17 cells in the acute response to OPC. Thus, STAT3 likely modulates 
antifungal immunity beyond the hematopoietic compartment. Indeed, our data demonstrate for the 
first time that STAT3 signaling in the oral BEL is required for protection against OPC (Fig. 4.3A, 
4.4A-C, 4.5). Supporting this, our group previously showed that HIES patients exhibit 
impairments in salivary antifungal immunity, with reduced levels of salivary AMPs including -
defensins and histatins [134]. STAT3 deficiency in lacrimal epithelial cells results in decreased 
IB expression, enhanced apoptosis and a Sjögren’s syndrome-like phenotype [304]. 
Interestingly, IB is key to NF-B mediated signaling downstream of IL-17RA [126]. STAT3 
also regulates metabolism in various settings to meet energy needs for cell proliferation, and 
STAT3-regulated functions in mitochondria is becoming increasingly appreciated [305-307].  
Our findings point to previously unappreciated roles of oral epithelial STAT3 in oral 
antifungal immunity. While it is conceivable that the IL-22/STAT3 axis coordinates antimicrobial 
immunity during OPC, it is also likely that oral epithelial STAT3 signaling may exert broader 
effects in oral antifungal immunity. Our findings therefore open up new questions regarding the 
role of BEL-specific STAT3 in vital oral antifungal events. 
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5.0 Unexpected Role of IL-22 in Secondary OPC 
5.1 Background 
The available human data and data from experimental animals have demonstrated a 
profound role for Th17/IL-17 signaling in oral antifungal immunity [74, 86, 87, 243, 264]. 
Although IL-17A is the eponymous Th17 cytokine, Th17 cells also produce IL-22, an IL-10 family 
cytokine, and is functionally relevant in acute OPC [308]. Unlike mice, humans exert adaptive 
responses to C. albicans due to early exposure in life and C. albicans colonizes mucosal surfaces 
as a commensal fungus in healthy subjects. Importantly, the functions of IL-17 and IL-22 are 
determined partly by the surrounding milieu. For example, as mentioned earlier, in bleomycin 
induced lung injury model, IL-22 is only protective in the absence of IL-17 [211]. The local tongue 
cytokine milieu during innate C. albicans response and the spectrum of responding cell types may 
be different from those induced in the tongue and surrounding draining lymph nodes in recall 
adaptive settings. In experimental autoimmune encephalitis (EAE), an autoimmune condition 
mediated by conventional Th17 cells, IL-17 signaling promotes proliferation and survival of lymph 
node FRCs [309]. While there is very little IL-17 expression or expansion of Th17 cells in the 
cervical lymph node during innate response to OPC, IL-17 responses are observed during recall 
C. albicans infection [37, 243]. 
In contrast to humans, mice do not have C. albicans as a commensal and therefore lack 
pre-existing C. albicans reactive Th17 cells. Instead, mice mount a robust antigen independent 
Type 17 response during their initial encounter with C. albicans which is complemented by 
conventional Th17 responses during a second encounter [37, 74, 86, 243]. On the other hand, 
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humans are exposed to C. albicans early in life and generate potent C. albicans-specific Th17 
cells. Consistent with the antigen-independent activation of innate type 17 cells, Card9-/- mice are 
resistant to acute OPC but are sensitive to recall C. albicans infection. This sensitivity is attributed 
to the failure to generate conventional Th17 responses in C. albicans recall infection in Card9-/- 
mice [53]. In addition to IL-17A and IL-17F expression, Th17 cells also produce IL-22. Despite 
the differences observed in Card9-/- mice, the independent roles of IL-17A and IL-22 in recall C. 
albicans infections have not been assessed. 
During adaptive immune responses, the surrounding draining lymph nodes are major sites 
of antigen dependent immune activation, and T cells subsequently egress to the local environment 
to exert effector functions. The lymph node stromal environment actively dictates lymphoid 
effector functions [310-313]. In lymphocytic choriomeningitis virus (LCMV) infection, IL-22 
deficiency causes thymic and splenic hypertrophy and promotes T cell effector functions in 
lymphoid organs [217]. IL-22 has also been shown to be important in secondary and tertiary 
lymphoid organ (SLO and TLO) architecture. In this adenovirus cannulation model, IL-22 is 
thought to act on TLO stroma to produce CXCL-13 and CXCL-12, which trigger B-cell clustering, 
lymphoid aggregation and autoantibody production [314]. Similarly, IL-22 promotes thymic 
epithelial cell regeneration in response to thymic injury, a function that is important for restoring 
immune competence after physical or pathological insults [140]. IL-22 has also been shown to 
modulate MHC Class II expression and IFN- responses during skin Staphylococcus epidermidis 
colonization [218]. Hence the outcomes of IL-22 deficiency may not be limited to the stromal 
compartment alone but can also direct lymphocyte functions in a context dependent manner.  
These reports indicate that although most immune cells do not express IL-22RA1, IL-22 
can have essential indirect immune modulatory functions on lymphocytes. Such activities are 
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likely to be prominent in settings of chronic inflammation and antigen exposure that promote TLO 
formation and adaptive responses. I therefore sought to determine the role of IL-22 in the adaptive 
response using our previously developed oral C. albicans recall infection model. In this system, 
mice are sublingually inoculated with C. albicans, rested for 6-8 weeks in order to permit 
development of adaptive responses, and then re-infected to assess the nature of the immune recall 
response. As shown in this chapter, I found that IL-22 is induced in secondary OPC and it is 
protective. Surprisingly, IL-22 deficiency also appeared to result in enlarged cLN in the context of 
recall C. albicans infections, a phenomenon that was not seen during the primary response. This 
expansion was accompanied by decreased CD4+ T cell proliferation, decreased CD4+IFN+ 
frequencies and elevated CD4+IL-17A+ frequencies. Therefore, during the adaptive response to 
oral C. albicans challenge, IL-22 appears to act on the cervical LN (cLN) stroma to modulate CD4 
effector function. 
5.2 Results 
5.2.1 IL-22 is induced during primary and secondary Candida infection 
We previously developed a model of secondary (recall) oral Candida infection to assess 
the role of the adaptive response in OPC. Using this system, we demonstrated that Th17 cells 
indeed confer long term protection against OPC [243]. Given the context-dependent role of IL-22 
in acute and chronic infection/inflammation models, we sought to determine the role of IL-22 
during adaptive (recall) Candida infections. C. albicans specific IL-22-producing CD4 T cells 
 86 
have been described in humans  but they have not been assessed in mice in the context of OPC 
[151, 265, 315].  
To assess the state of IL-22 expression during secondary OPC, WT mice were subjected to 
OPC. Six to eight weeks after the primary exposure, mice were orally re-challenged with C. 
albicans, and PBS-inoculated mice were used as negative controls (Fig. 5.1A). Tongue was 
harvested at day 2 post infection and Il17a and Il22 expression was assessed. As previously 
reported [37, 74, 308], both Il17a and Il22 were induced after primary oral Candida infection. 
Similarly, Il17a and Il22 were upregulated during secondary OPC, although surprisingly there 
were no statistical differences observed between the primary and secondary infection (Fig. 5.1B, 
C). To confirm the antigen specificity of responding lymphocytes, cervical lymph node (cLN) 
cells were harvested at day 3 post re-challenge and stimulated with heat-killed (HK) C. albicans 
for 5 days. IL-17A and IL-22 were assessed in the supernatants by enzyme-linked immunosorbent 
assay (ELISA). As previously reported, there was a robust expression of IL-17A (~5000 pg/ml) 
after re-challenge. Mice receiving only a primary infection also expressed IL-17A (~1000 pg/ml) 
but IL-17A was undetectable in sham-infected mice (Fig. 5.1D), as previously described 
(Hernandez Santos et al., 2013). IL-22 expression followed a similar pattern, with ~2500 pg/ml 
IL-22 seen during recall challenge and ~1000 pg/ml in mice subjected to only primary infection 
(Fig. 5.1E). Therefore, C. albicans-specific IL-17A and IL-22 responses are induced during recall 
Candida infection, although it seemed that there was higher magnitude of cLN IL-17A expression 
compared to IL-22 during the adaptive response. 
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Figure 5.1: C. albicans specific cLN lymphocytes express IL-17A and IL-22 during recall 
OPC 
(A) Recall OPC infection model diagram showing timelines of infection and harvest. WT mice 
were orally challenged with C. albicans (primary OPC) or phosphate-buffered saline (PBS-sham). 
Six weeks later, mice were re-infected with C. albicans or treated with PBS. Tongue and cervical 
lymph nodes cLN were harvested at the indicated time points. Total mRNA from day 2 tongue 
homogenates of infected WT mice was subjected to qPCR for Il17a (B) and Il22 (C) and 
normalized to Gapdh. CLN cells were harvested at day 3 post primary and secondary OPC and 
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cultured ± heat killed (HK) C. albicans for 5 days. IL-17A (D) and IL-22 (E) in supernatants were 
assessed by ELISA. Graphs show mean +SEM and each symbol represents a mouse. Data were 
analyzed by ANOVA. *p<0.05, ***p<0.001. 
5.2.2 IL-22 protects against persistent oral C. albicans infection 
To assess the functional relevance of IL-22 during the adaptive response to oral C. albicans 
infection, wild type (WT) and Il22-/- mice were subjected to a recall OPC model, and fungal 
burdens were assessed at days 1 to 3 post infection. During both primary and recall OPC, WT mice 
largely cleared the infection (primary infection average CFU~ 132, recall infection average CFU~ 
32) while Il22-/- mice still had significantly higher fungal burdens at day 3 p.i. (primary infection 
average CFU~2964, recall infection CFU~1350) (Fig. 2A, B). WT mice that received both primary 
and recall infections had a slightly lower but statistically insignificant decrease in fungal burden 
(Fig. 2B). A lower percentage of these mice (33.3%) still had detectable fungal burdens at day 3 
compared to those receiving only a primary infection, where 50% failed to clear C. albicans (Fig. 
2C). In contrast, Il22-/- mice maintained higher fungal burdens and persistent colonization during 
both primary and recall challenge (Fig. 2C). Therefore, prior exposure to C. albicans induces a 
modestly more efficient pathogen clearance in WT mice, while IL-22 deficiency resulted in 
impaired clearance and persistent colonization. 
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Figure 5.2: IL-22 protects against persistent C. albicans colonization 
WT and Il22-/- mice were subjected to primary and secondary OPC. PBS inoculated group was 
maintained as sham control. Tongues were harvested on days 1, 2 and 3 p.i. and fungal burdens 
were assessed by enumerating colony forming units (CFU) of tongue homogenates on agar plates. 
(A) Data show mean CFU at the indicated time points +SEM for primary OPC (left) and secondary 
OPC (right). Data is from one experiment with 4-5 mice per group per time point. (B)  CFUs 
assessed at day 3 as in panel (A). Bars show geometric mean + SD. Dashed lines represent the 
limit of detection. Data were pooled from 3 experiments and each symbol represents a mouse. (C) 
Analysis of data from panel B showing the percentage of mice with fungal burden. Data were 
analyzed by ANOVA, with Mann-Whitney correction for fungal load analysis. *p<0.05, **p<0.01, 
***p<0.001,   ****p<0.0001.    
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5.2.3 IL-22 may regulate cLN structure and cLN IL-17 responses during secondary OPC 
To assess the nature of the T cell compartment during a recall (adaptive) response to oral 
C. albicans infection, we turned our focus to the draining cLN, a major site of immune activation 
in response to oral insults. There were few notable differences in cLN from WT sham, WT primary 
OPC and WT re-challenged mice (Fig. 5.3A, B). Unexpectedly, we observed that Il22-/- mice had 
larger cLN than their WT counterparts, and this difference was most prominent in re-infected Il22-
/- mice (Fig. 5.3A, B). Since antigen-specific Th17 cells mediate protection against secondary OPC 
[129, 243], we first hypothesized that the enlarged cLN observed in Il22-/- mice may be due to 
increased proliferation of CD4 T cells undergoing priming. However, this appeared not to be the 
case, as cLN CD4 T cells from Il22-/- mice had lower proliferative capacity than WT CD4 T cells, 
as assessed by Ki67 staining (Fig. 5.3C-E). Hence the enlarged cLN in Il22-/- mice is not likely 
due to proliferative expansion of CD4 T cells.  
This observation led us to evaluate the cytokine output and activation state of cLN T cells, 
measured at day 3 after either a primary or secondary C. albicans infection. While there was no 
difference in the frequency of CD4+ IFN+ cells in WT mice regardless of the number of infections, 
there was a decreased trend for IFN+ CD4+ cells in Il22-/- mice particularly during secondary 
infection (Fig. 5.4A, B). There was a small but statistically significant increase in CD4+ IL-17A+ 
cells in WT mice during secondary infection (averaging 1.5%) compared to WT and Il22-/- mice 
subjected to only primary infection (Fig. 5.4A, C). Unexpectedly, there were even higher 
frequencies of CD4+ IL-17A+ cells (~ 2.5%) in Il22-/- cLN following secondary infection (Fig. 
5.4A, C). The activation state of IFN+CD4+ and CD4+IL-17A+ cells was evaluated by co-staining 
with CD44, a marker for effector-memory T cells (TEM). While there was little change in the 
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frequency of CD4+CD44+ IFN+ cells in WT mice, there was ~10% decrease in CD4+CD44+ IFN+ 
cell frequency in Il22-/- mice during secondary infection (Fig. 5.5 A, B). In contrast, the frequency 
of CD4+CD44+IL-17A+ cells increased in WT mice (~9%) in response to secondary infection (Fig. 
5.5 A, C). The absence of IL-22 resulted in even higher frequency of CD4+CD44+ IL-17A+ cells 
(~14%) during secondary infection. Together, these data suggest that IL-22 deficiency promotes 
effector Th17 activity during secondary OPC.  
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Figure 5.3: Il22 deficiency increases cLN size and impairs CD4 proliferation during 
reinfection 
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WT and Il22-/- mice were subjected to primary and secondary OPC. PBS inoculated group was 
maintained as sham control. (A) Diagram and (B) summary plot showing the increase in cLN size 
at day 3 post infection. Data is representative of 3 independent experiments. Harvested cLN cells 
were stained and gated on live TCRB+CD4+Ki67+ cells. Representative histogram (C) and (D) 
summary plot showing Ki67 MFI in the treatment groups. (E) Representative FACS plot showing 
Ki67 staining as in (C) and (D).  (F) Left; Summary plot and right; fold expansion of 
TCRB+CD4+Ki67+ cells in WT and Il22-/- mice during reinfection. Data are from 1 experiment. 
Each symbol represents a mouse. Data were analyzed by ANOVA *p<0.05, ****p<0.0001.    
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Figure 5.4: IL-22 modulates CD4IFN-+ and CD4IL-17A+ cell frequency during secondary 
OPC 
WT and Il22-/- mice were subjected to primary and secondary OPC. PBS inoculated group was 
maintained as sham control. Harvested cLN cells were stained and gated on live 
TCRB+CD4+IL17A+ and TCRB+CD4+IFN+ cells. (A) Representative FACS plot (B). 
Quantification of TCRB+CD4+IFN+ cells and (C) TCRB+CD4+IL17A+ from A. Data is from 1 
experiment and each symbol represents a mouse. Data were analyzed by ANOVA *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.    
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Figure 5.5: IL-22 modulates the activation state of CD4IFN-+ and CD4IL-17A+ cells 
during secondary OPC 
WT and Il22-/- mice were subjected to primary and secondary OPC. PBS inoculated group was 
maintained as sham control. Harvested cLN cells were stained and gated on live 
TCRB+CD4+CD44+IL17A+ and TCRB+CD4+CD44+IFN+ cells. (A) Representative FACS plot 
(B). Quantification of TCRB+CD4+CD44+IFN+ cells and (C) TCRB+CD4+CD44+IL17A+ from 
A. Data is from 1 experiment and each symbol represents a mouse. Data were analyzed by 
ANOVA *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.    
0
10
20
30
%
 o
f 
C
D
4
4
+
IF
N
g+
Wildtype              Il22-/-
***
*
****
*
****
0
5
10
15
20
%
 o
f 
C
D
4
4
+
IL
-1
7
A
+
Wildtype              Il22-/-
Sham 
Primary OPC 
Secondary OPC
**
***
*
****
****
IFNƔ
IL
-1
7
A
Sham Primary OPC Secondary OPC
Il22-/-
WT
 A 
 B  C 
 96 
5.3 Discussion 
Unlike humans, mice are naïve to C. albicans and provide a suitable experimental system 
to interrogate the roles of IL-22 during innate and adaptive response to oral C. albicans infection. 
In this study, I sought to understand the role of IL-22 during recall (adaptive) responses to oral 
thrush. Both, IL-17A and IL-22 were induced in murine tongue during the innate and adaptive 
response to OPC (Fig. 5.1) [37, 53, 74, 243, 308]. Robust C. albicans-specific IL-22 and IL-17 
expression was observed when cLN cells were co-cultured with HK Candida under recall settings. 
Thus IL-22 responses are locally induced in the tongue as well as in the peripheral draining cLN 
during adaptive response to oral C. albicans challenge. Other studies have demonstrated recall IL-
22 responses when peripheral blood from healthy donors were stimulated with HK Candida [151, 
265, 315]. Recall IL-22 responses are therefore present in humans and generated in mice in 
response to experimental C. albicans infection. 
Conventional Th17 cells generated during the adaptive response do appear to augment the 
innate Type 17 response to promote antifungal immunity, as would be expected for an adaptive 
response. Pre-exposure to oral C. albicans challenge modestly enhanced clearance and reduced 
prolonged colonization (Fig. 2. A-C) [53, 243]. However, Il22-/- mice had sustained fungal burdens 
and persistent colonization regardless of previous encounter with C. albicans (Fig. 2. A-C). In the 
current experimental set up, it is hard to tell whether the observed fungal burden during the recall 
challenge is a failure of adaptive IL-22 mediated responses or a carry-over effect of Il22 deficiency 
from the innate response. As noted previously, mice mount a robust innate Type 17 response 
against primary C. albicans exposure [74, 243].  Since the innate response drives the unset of 
adaptive immunity, it is conceivable that the failure to clear C. albicans is due to the accrued loss 
of IL-22 driven protection from the primary and secondary exposure.  
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Innate Type 17 cells (mainly TCR+and TCR+ cells) are the sources of IL-17A, IL-17F 
and IL-22 during primary OPC [86, 308, 316]. Surprisingly, both TCR-/- and TCR-/- mice are 
resistant to OPC while Rag-/- mice are susceptible [74, 242]. Similarly, CD4 but not CD8 T cells 
are the dominant source of IL-17 during adaptive responses to oral C. albicans challenge. 
However, CD4-/- and CD8-/- mice are resistant to OPC. These outcomes are attributed to 
compensatory mechanisms during the primary genetic deficiency. In recall C. albicans infection 
in WT mice, CD4 but not CD8 T cells are the dominant source of IL-17A. However, in C. albicans 
rechallenged CD4 or CD8 deficient mice, there was a comparable increase in CD8IL-17A+ and 
CD4IL-17A+ cells respectively [243]. Although the consequence of Il17a deficiency in the 
adaptive response to C. albicans has not been assessed, it is remarkable that Il22 deficiency by 
itself impairs antifungal immunity during both primary and secondary exposure to oral C. albicans 
challenge.  
Immune cell infiltration and translocation of C. albicans to the cLN could hypothetically 
have accounted for increased cLN size observed in Il22-/- mice during re-infection. However, upon 
culturing cLN cells with HK candida in medium lacking any antifungal drug, there was no 
evidence of hyphal growth or cloudiness in the media (data not shown). This observation suggested 
that the enlarged lymph node could not be due to translocation of live Candida to the cLN. 
Although the total numbers of immune cells infiltrating the cLN were not assessed in this 
experiment, the decreased proliferative capacity of CD4 T cells from Il22-/- mice (Fig. 5.3 C-F) 
during reinfection indicates that the increased cLN size is not likely due to aberrant CD4 T cell 
expansion. Instead, IL-22 may be acting on the cLN stroma during C. albicans reinfection to 
modulate the cLN stroma and promote CD4 T cell expansion. In contrast to the impaired CD4 
proliferation observed in Il22-/- mice during C. albicans reinfection, IL-22 exerted opposing 
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modulatory effects on cLN CD4 IFN and IL-17A cell frequencies. While the frequency of IL-
17A+ CD4 T cells and CD44+CD4+IL-17A+ cells were elevated in Il22-/- mice during reinfection, 
CD44+CD4+IFN+ cells were decreased. It therefore appears that IL-22 acts to dampen cLN IL-
17A output during C. albicans reinfection while promoting IFN responses. A previous report 
showed increased Il17a and IFN  transcripts in Il22-/- mice in a gastric C. albicans infection 
model. Here, it was suggested that IL-22 exerts reciprocal regulation of IL-17A and IFN- . 
While there are major differences between the gastric candidiasis and OPC model, it appears that 
some common facets of IL-22 mediated responses may apply to both settings. 
Our understanding of Th17 memory cells is still evolving. Th17 cells are plastic and 
frequently interconvert between Th1 and Treg phenotypes [254, 317]. Using IL-17 fate tracker 
mice, the capacity of Th17 cells to convert into Th1 cells and dual expressing IL-17A+IFN+ cells 
was demonstrated in the setting of chronic autoimmunity. However, this switching did not occur 
in acute dermal candidiasis, which is -T cell predominated [254]. In our hands, very few IL-
17A+IFN+ CD4 T cells were present in WT or Il22-/- mice during reinfection, suggesting that there 
is limited plasticity in the Th1 and Th17 populations. Moreover, the opposing effects of IL-22 
deficiency on IL-17A and IFN- was observed only during reinfection. IFN- is documented to 
inhibit Th17 differentiation through enhanced STAT1 activation [318, 319]. It is therefore likely 
that IL-22 may be modulating cLN Th17 responses through IFN--expressing Th1 cells. Although 
Th17 cells and IL-17RA signaling are important in protecting against oral thrush [74, 86, 243], 
exuberant Th17 responses may also promote inflammation and tissue pathology.   
Regardless of these opposing effects of IL-22, our data so far suggest that during oral C. 
albicans recall infection, IL-22 modulates T cell responses and the cLN environment. Although 
IL-22RA1 expression is reported to be restricted to cells of non-hematopoietic origin, IL-22RA1 
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expression has been validated on thymic epithelial cells during thymic injury [140] and on lymph 
node stromal cells in a model of collagen-induced arthritis (CIA) [313]. In the CIA model, IL-
22RA1 signaling on the LN stroma promoted germinal center reactions [313]. In a related study, 
it was demonstrated that the lymphoid stroma inhibits activated T cell proliferation [311].  
Interestingly, the lymph node stroma also modulates sphingosine 1 phosphate (S1P)/ 
sphingosine 1 phosphate receptor (S1PR) signaling to control emigration of activated T cells from 
the lymph node [310, 320]. Therefore, a plausible alternative explanation for the increased 
frequency of Th17 responses and cLN hypertrophy in the absence of IL-22 could be due to the 
failure of Th17 cells to egress from the cLN into the local tongue tissue to exert antifungal 
immunity. IL-22 signaling modulates the sphingosine1 (S1P) sphingosine receptor axis (SIPR) in 
metastatic cancer to promote macrophage infiltration [321]. The observations in our study will 
therefore be consistent with a speculation that IL-22 acts on the cLN stroma during adaptive oral 
C. albicans infection to modulate T cell effector functions and egress. Although germinal center 
responses were not assessed in these experiments, a related study in experimental autoimmune 
encephalitis (EAE) showed that, while IL-17 signaling in fibroblastic reticular cells of the lymph 
node was not required for Th17 development, it was important for germinal center formation and 
antibody production [309]. 
To date, there are no licensed antifungal vaccines, but an experimental vaccine for C. 
albicans is in development. NDV-3, a recombinant alum conjugated vaccine based on the fungal 
cell wall invasion protein agglutinin-like sequence 3 (Als3p) is the most clinically advanced. In 
phase 1 clinical trials, NDV-3 was well tolerated and induced antigen specific production of           
IL-17A and IFN- [322]. NDV3 also elicited moderate protection in animal models of 
oropharyngeal, vaginal and invasive candidiasis through T and  
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B cell mediated responses [323-325]. Moreover, this vaccine was cross protective against 
Staphylococcus aureus (S. aureus) infection due to high structural homology between Als3p and 
S. aureus clumping factor-A. Since recipients of fungal vaccines are likely to be persons with 
underlining immunocompromised conditions, it is imperative to identify correlates of protection 
and their underlying mechanism(s) of action in order to boost appropriate immunity to the extent 
possible. The findings of this study reveal perturbations in the Th17 response and lymph node 
structure in the absence of IL-22 and open new questions to understand how IL-22 and IL-17 
collectively shape the adaptive response to oral thrush.  
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6.0 Conclusions and Future Directions 
6.1 Summary 
In this dissertation, I expanded the field’s understanding of the mechanisms underlying IL-
22 mediated protection in the setting of acute OPC (innate response) and in response to 
recall/secondary OPC (adaptive response). In chapter 3, I found that IL-22 is non-redundant with 
IL-17RA signaling in mediating protection against OPC. Among their key differences in driving 
antifungal events was the finding that IL-22 and IL-17RA signaling exerted opposing effects on 
neutrophil recruitment. While IL-17RA signaling promotes neutrophil recruitment, IL-22 dampens 
neutrophil recruitment. Moreover, IL-22RA1 was found to be expressed in an anatomically distinct 
region from IL-17RA in the stratified oral epithelium. While IL-17R is required in the SEL to 
protect against OPC, IL-22RA1 is required in the underlying BEL. IL-22 is required to drive 
proliferation of BEL cells which in turn give rise to the differentiated SEL cells which express IL-
17RA. Together, these data support the spatially distinct roles of IL-17RA and IL-22RA1 during 
OPC and show that IL-22 signaling in the BEL promotes the replenishment of the sloughed SEL 
and hence licenses IL-17R signaling in the SEL to drive antifungal immunity in the oral mucosa. 
 In chapter 4, I identified an additional role of STAT3 in oral thrush besides its known roles 
of promoting protective Th17 responses. I found that STAT3 signaling in the BEL is required for 
protective oral antifungal immunity. STAT3 was identified as a key transcriptional hub integrating 
IL-22 and IL-17RA signaling networks. Notable among these targets are I C/EBP Fos, 
JUNB, MYC, BCL3, the RNA binding protein ZFP36 (better known as tristetraprolin) and the 
receptors Il1RN and CXCR3. Thus, in addition to promoting differentiation and maintenance of 
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Th17 cells, BEL STAT3 co-ordinates antifungal immunity by targeting key transcriptional events 
in the responding or C. albicans invaded epithelial cells. 
In chapter 5, I assessed the role of IL-22 in recall/adaptive OPC setting. Il22-/- mice are 
sensitive to secondary OPC although it remains to be determined whether their sensitivity is due 
to accrued defects from the primary exposure. Regardless of this caveat, IL-22 deficiency in recall 
OPC setting resulted in increased cLN size and weight despite decreased proliferation of cLN CD4 
cells. Moreover, IL-22 deficiency promoted IL-17A Th17 effector activity while hampering IFN-
 responses  These data highlight potential differences in the role of IL-22 in the oral mucosa and 
the cLN during acute and recall oral C. albicans exposure. In recall C. albicans exposure settings, 
IL-22 modulates cLN structure and effector CD4 responses. These findings support a model where 
IL-22 signaling in the cLN stroma likely modulates cLN structure and organization and effector 
CD4 T cell responses and possibly egress during OPC. 
Together, these findings bring to light many previously unappreciated mechanisms of oral 
antifungal immunity and point to the co-ordination among key cytokines, immune cells, oral 
epithelial cells and transcription factors to elicit appropriately toned protective antifungal immune 
responses. Although IL-22 and IL-17RA signaling work in concert to drive oral antifungal 
immunity, there are some notable differences in in their mechanisms of action, localization of their 
responding receptors in the oral epithelium as well as the downstream signaling pathways they 
activate. Even more revealing is how signaling through their disparate receptors is integrated in 
the responding epithelial cells to mount effective antifungal immunity. Additionally, we identified 
a role for IL-22 in cLN during adaptive C. albicans response partly through elevated IL-17A 
response. This finding has implications for understanding the roles of IL-22 on cLN stroma and 
how it shapes effector T cell responses.  
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6.2 Unifying Discussion, Outstanding Questions and Future Directions 
Our current and previous findings on the activation requirements for IL-17 and IL-22 
production in OPC reveal important and intricate roles for candidalysin and IL-23. While the role 
of IL-23 in maintaining effector functions of conventional Th17 cells is well known, the 
mechanisms by which IL-23 activates IL-17 and IL-22 production from innate immune cells in 
OPC (mainly TCR+ and   cells, as shown here) is less understood. In conventional Th17 
cells, IL-23 induces STAT3 activation and upregulation of RORT to promote Th17 effector 
functions and maintenance [97]. However, deletion of STAT3 in CD4 T cells did not exacerbate 
susceptibility to OPC [86]. Candidalysin promotes innate TCR+ cell expansion and Il17 induction 
during OPC [37]. In our current study, candidalysin was also important for IL-22 expression during 
OPC. It is thought that candidalysin triggered IL-1 signaling from the hematopoietic and stromal 
compartments account for this observation [37]. However, the direct mechanisms of how 
candidalysin induces TCR and   cell activation is still unclear.  cells and tissue resident 
CD4 T cells have been described in many mucosal tissues where they are poised to respond quickly 
to insults and injury [326, 327]. Similar responses are important for eliciting a fast response to oral 
C. albicans infection, and it will be interesting to understand more about how candidalysin 
activates  cells and oral resident CD4+ T cells during OPC. In this regard, EGFR was recently 
determined to be required for candidalysin mediated signaling on epithelial cells [36]. EGFR is 
expressed in immune cells [328-330] and it will be important to determine whether candidalysin-
mediated EGFR signaling on + and TCR+ cells directly contributes to Type17 cell responses 
in OPC.  
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Beyond candidalysin, there is likely to be more roles for DAMPs released during Candida 
hyphal invasion in the activation of “Type 17” cells. Hyphal invasion induces damage to the 
epithelium leading to apoptotic and necrotic cell death [331]. Necrosis can lead to the release of 
various DAMPs including mitochondrial DNA, N-formyl peptides, cardiolipin, cytochrome C, 
carbamoyl-phosphate synthase 1, ATP and calreticulin which can have varied effects on 
inflammation and effector cell responses [332-336]. Particularly, ATP signaling through P2X7R 
promotes inflammasome activation leading to the production of IL-1 which is necessary for Th17 
differentiation [267, 337]. Similarly, calreticulin promotes Th17 differentiation through enhanced 
IL-6 and TNF- secretion [336]. Hence, there is a likely role for DAMPs in the activation of “Type 
17” immunity during OPC although most of these are yet to be experimentally determined.  
In determining the cellular sources of IL-22 during OPC, we found that  cells but not 
TCR+  cells were the dominant source of IL-22, which contrasts somewhat with our previous 
observations regarding sources of IL-17A. Although one study suggested the presence of IL-17 
producing ILCs in OPC [117], it is clear that the dominant cellular sources of IL-17 and IL-22 in 
OPC are TCR+  and   cells, respectively. While it is likely that dual producers of IL-17 and IL-
22 will exist in these populations, technical challenges in obtaining viable cells for flow cytometry 
from this tissue prevented us from assessing this. Our current isolation protocol coupled with the 
use of IL-17 and IL-22 dual reporter mice will be useful in fully delineating the cellular sources of 
IL-17 and IL-22. However, the direct assessment of the functional relevance of IL-17 and IL-22 
producing TCR+  and   cells in OPC is also challenging because of the very low proportions 
of cells that can be isolated from the tongue, making it impossible to do adoptive transfer studies. 
Moreover, both TCR−− and TCR−− mice are resistant to OPC, although Rag1-/- mice are 
sensitive. Hence there is a likely compensatory mechanism at play [86, 243]. Thus, while dual 
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producers of IL-17 and IL-22 can be assessed in future studies, it is not very likely that the 
functional relevance of IL-17 and IL-22 producing TCR+  and   cells in OPC can be directly 
assessed. 
Mucosal barriers are uniquely adapted to provide and support immune responses in their 
respective niches. Compared to other barrier sites like the skin, gut and lung, the mucosal 
immunosurveillance networks in the oral cavity are poorly understood. The oral cavity has niches 
such as the tongue, gingiva, buccal mucosa, tonsils and hard palate that are adapted to limit 
excessive inflammation, promote tissue repair and maintain the oral microbiome. Findings from 
our current study show that, unlike IL-17RA [88], IL-22RA1 is localized and required in the BEL 
to promote oral antifungal immunity.  
This discovery opens up opportunities to interrogate the functional consequences of IL-
22RA1 signaling in the BEL. An unanswered question is whether early oral exposure to C. 
albicans in humans (for example, in vaginal delivery) confers any adaptations to the oral 
epithelium that enable it to better deal with later assaults in life. This early exposure occurs long 
before introduction to solid food which likely causes masticatory stress to the oral cavity [338]. In 
this regard, a recent seminal paper demonstrated that prior inflammatory assault or C. albicans 
infection in the skin confers epithelial stem cell memory in K14+ cells to respond better to 
subsequent wounding [270], but it is unknown whether something similar occurs in the oral 
epithelium.  
Moreover, the BEL is home to stem cells but comparatively little is known about how they 
impact oral immunity [81, 82]. Lrg1+ and Lrg5+ stem cells have been described in the hard palate 
and dorsum of tongue respectively [77, 79]. In the hard palate, Lrg1 stem cells maintain quiescence 
during homeostasis but lose their dormancy in response to wounding and masticatory stress [77]. 
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Whether stem cells in the oral cavity express IL-22RA1 or not and their role in oral antifungal 
immunity and oral mucosal immunity in general is not known.  
In addition to contributing to oral antifungal immunity, IL-22/IL-22RA1 in the oral BEL 
may impact other aspects of oral immunity including oral malignancies. Oral squamous cell 
carcinoma (OSCC), which mostly occurs on the tongue and floor of the mouth, is a common 
manifestation in head and neck cancer patients with poor prognosis [339]. Chemotherapy and 
radiotherapy in these patients are often complicated by increased risks of oral and gastrointestinal 
candidiasis and candidemia [340-342]. This complication is partly driven through epithelial 
interactions with Candida. Models of oral cancer target mutations in basal epithelial cells to induce 
malignant transformation [339]. The role of IL-22RA1/STAT3 in maintaining stemness in other 
cancers including pancreatic cancer, colon cancer, have been described [343]. The localization of 
IL-22RA1 in the oral BEL suggests a potential role for IL-22RA1 expressing stem cells in OPC. 
This finding may be translatable to the roles of IL-22RAI in Lrg5+ stem cells in the intestinal 
epithelium, as were shown in a recent study. In one report, IL-22RA1 signaling in intestinal stem 
cells protects against colon cancer incidence and genotoxic stress [216]. Thus, assessing the role 
of BEL IL-22RA1 in OSCC and oral genotoxic stress will be revealing. Whether oral BEL IL-
22RA1/STAT3 has roles in oral malignant transformation and OSCC is not appreciated. Our 
current findings of the role of BEL IL-22RA1 and STAT3 provide further impetus to understand 
how these pathways could influence oral malignancy. By subjecting Il22ra1K14Ert2Cre, 
Il22ra1Lrg5Ert2Cre, STAT3K14Ert2Cre and STAT3Lrg5Ert2Cre mice to radiation induced mucositis and 
OPC, some of these pertinent questions can be addressed. 
In view of the masticatory stress, constant damage, exposure to food allergens and 
microbes encountered in the oral cavity, it is conceivable that the stratification and spatial 
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distribution of IL-17RA and IL-22RA1 may serve broader functions to maintain homeostasis in 
oral immunity. However, our understanding of the relationships between the cells in the stratified 
oral epithelium is still very rudimentary. The findings made in this dissertation can help lay the 
foundation for deeper investigations. Newly available tools such as spatial transcriptomics will be 
valuable for the assessment of the relationships in the various cell types present in the oral 
epithelium while providing critical information on their transcriptional profiles. 
The impact of good oral health on general well-being has been long appreciated.  
Degeneration of oral health as in oral thrush and periodontitis are associated with worsened 
outcomes in diabetes, gut inflammatory conditions and cardiac health [3, 344, 345]. A recent 
publication highlighted the intramucosal connection between the oral cavity and the gut in 
commensal pathobiont driven colitis. Oral microbes and pathobiont reactive Th17 cells generated 
in the cLN in response to periodontitis translocate to the gut to exacerbate gut inflammation [345]. 
This current study and previous findings highlight the importance of IL-17RA and IL-22RA1 
signaling in the oral mucosa in protecting against both oral thrush and periodontitis [3, 74, 86, 
308]. However, studies on how the oral immunosurveillance networks driven by OEC IL-17RA-
IL-22RA1 lead to oral dysbiosis are lacking. Moreover, it is not clear whether abrogation of IL-
17RA and IL-22RA1 signaling in OECs leads to altered translocation of Candida to the gut. 
Whether Th17 cells generated in response to recall OPC in the cLN translocate to the gut to 
mediate extra-oral functions is not appreciated either. In both mice and humans, cross protective 
C. albicans specific Th17 cells are expanded during intestinal inflammation, presenting increased 
risk for pulmonary infections [151, 265, 266]. Those studies suggest that breakdown in oral 
epithelial immunosurveillance networks can potentially induce C. albicans-mediated dysbiosis 
and gut inflammation. Studies to investigate this have been lacking partly due to an absence of 
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adequate systems to study the oral mucosa. However, findings from our study and currently 
available tools (I17raK13Cre, Il22ra1K14Ert2Cre, I17raK13Cre x Il22ra1K14Ert2Cre and Il22ra1-/-x 
Il17ra-/-) will allow these pertinent questions to be addressed.  
Data from our transcriptomic analysis of Il22-/- and Il17ra-/- mice shed light on the genes 
and pathways employed by the host to prevent or limit OPC. The central role of STAT3 in the 
transcriptional hub (Fig. 4.2) and the subsequent demonstration of its requirement in the BEL was 
unexpected since previous studies have relied on the role of STAT3 in Th17 cells to explain the 
disease in HIES patients (Fig. 4.4). Our observation raises many questions. Paramount among 
them is what are the targets of BEL STAT3 and their role in oral antifungal immunity? Our 
bioinformatic analyses suggest that STAT3 may be integrating signals from IL-17RA signaling 
and other pathways to promote optimum antifungal immunity. In this transcriptional network, 
STAT3 is connected with I a key IL-17-induced transcription factor important for induction 
of IL-17 target genes [125, 126]. Although not carefully defined in OPC, studies from other models 
show the link between epithelial STAT3 and I For example, a model of Sjögren’s syndrome 
showed that disruption of I induction in lacrimal basal epithelial cells exacerbates disease. 
Importantly, expression of I was dependent on K5-driven STAT3 [304]. Analysis of the I 
promotor activity showed that, while IL-17 does not activate STAT3, STAT3 is required for I 
promoter activity and induction of Defb4 (BD2, the human orthologue of mouse BD3) in HaCat 
cells (a human skin keratinocyte cell line) [346]. Similarly, IL-36-induced I in HaCat cells 
required STAT3 activity and is linked to impaired induction of some canonical IL-17 target genes 
[284]. The role of I in OPC is not clearly defined, and it is not known whether I is targeted 
by BEL STAT3. The roles and targets of STAT3 in BEL can further be inferred by analyzing BEL 
cells from K14CreERT2YFP+/-STAT3fl/fl mice and K14CreERT2YFP-/-STAT3fl/fl by RNASeq, ChIPSeq 
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and ATACSeq. Through these analyses, the central role of STAT3 can be further deconvoluted 
and the targets of oral epithelial STAT3 in OPC can be more clearly defined. By comparing these 
targets with the known IL-17RA transcriptomic data in OPC, there will be more clarity on how 
IL-22 driven STAT3 activation links with IL-17RA transcriptional network in OPC. Moreover, 
through ATACSeq analysis, epigenetic marks induced by STAT3 on target genes can be identified. 
This analysis will help us to understand whether STAT3 likely mediates epigenetic changes and 
chromatin accessibility of target genes besides the transcriptional regulation.  
There is a dynamic reciprocal balance between STAT3 and STAT1 signaling in many 
settings, leading to switches from proliferative to apoptotic or from inflammatory to anti-
inflammatory responses [184, 347]. For example, STAT1 gain of function mutations are associated 
with decreased STAT3 activity in CD4 cells, and the inverse is observed in STAT3 gain of function 
mutations [101-103]. The ultimate cellular response is therefore dependent on the cross talk 
between these transcription factors, which is regulated by environmental cytokines, the duration 
of stimulation, and the magnitude of activation [184, 347]. Thus, it will be important to know 
whether deletion of BEL STAT3 results in any aberration in STAT1 mediated responses during 
OPC. The mice created in this project (STAT3K14ERT2 mice) will be a useful system in which to 
accomplish this. 
In addition to the transcriptional roles of STAT3, the pleotropic and even sometimes 
contrasting effects of STAT3 under physiological and pathological conditions can also be dictated 
by its subcellular localization and interactions with other signaling intermediates. Fungal invasion 
into the epithelium induces cellular stress, causing changes in membrane permeability, decreased 
mitochondrial fitness, increased generation of intracellular ROS, decreased intracellular ATP and 
calcium influx which involve the mitochondria. Mitochondrial STAT3 is known to be important 
 110 
in redox homeostasis and ROS generation [348, 349]. STAT3 S727 phosphorylation is known to 
modulate mitochondrial activity and bioenergetics [347]. Hence, whether STAT3 deficiency in the 
BEL affects organelles such as mitochondria or endoplasmic reticulum during OPC to respond to 
the ongoing stress is an outstanding question. 
As discussed in Chapter five, Il22 deficiency during recall/adaptive response to OPC 
appeared to result in visible changes in cLN size and associated effector CD4+T cell functions. 
The factors accounting for this observation are not known but there are two obvious hypotheses 
(1) IL-22 generated in the cLN during OPC may act on the lymph node stroma to alter T cell 
responses, and/or (2) IL-22 signaling may drive egress of activated T cells from the cLN to the 
tongue. Supporting these ideas, IL-22RA1 is expressed in stromal cells in the germinal center (GC) 
of the B-cell follicle during collagen induced arthritis [313]. It is yet to be determined whether IL-
22RA1 is expressed in the cLN in recall OPC settings and whether specific deletion of IL-22RA1 
from the cLN stroma recapitulates the responses seen in Il22-/- or Il22ra1-/- mice during adaptive 
T cell responses. Answering these questions will also allow for a more comprehensive assessment 
of changes in the cLN stromal and hematopoietic compartments. Lymph node hypertrophy in Il22-
/- mice could also be due to differential expression of lymphocyte retention and egress markers. 
Our bioinformatic analysis revealed increased CXCR3 expression in Il22-/- mice, which could 
potentially dampen Th17 recruitment to the tongue (Fig. 4.1C). A recent study showed that 
CXCR3 expression enhances CD8 T cell recruitment to the gut during HIV infection while 
impairing Th17 homing via the CCR6/ CCL20 axis [350]. Hence, it will be informative to 
immunophenotype the T cell infiltrate in the tongue and cLN to assess differences between effector 
T cells and expression of homing markers. Differences in the expression of CXCR3 may explain 
the impaired migration of Th17 cells from the cLN to the tongue.  
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In addition to the above hypothesis, an obvious line of investigation is to determine how 
IL-22 deficiency in adaptive OPC settings impacts on tissue resident memory T cells and the 
overall nature of the Candida specific T cell response. Both IL-17 and IL-22 induce factors 
including Ccl20 and Defb3 which ligate to CCR6 and potentially promote recruitment of Th17 
cells [351]. Given that “Type 17” cytokines induce local tissue-specific profiles that can influence 
recruitment, differentiation, homeostasis and protective functions of effector and memory T cells 
[352], it will be interesting to determine whether IL-22 deficiency distorts local responses that are 
necessary for generation and retention of tissue resident memory cells in the oral mucosa in 
adaptive OPC settings. Some of the currently available tools such as OVA-expressing C. albicans, 
pALS bearing MHC II tetramers and pALS-specific T cells from T cell receptor (TCR) transgenic 
mice can be used to address this question [244, 353]. For example, adoptive transfer of OVA-
specific T cells into WT and Il22-/- mice followed by infection with OVA-expressing C. albicans 
will allow for the characterization of (1) C. albicans induced memory T cells in the tongue and 
cLN and (2) IL-22 mediated local effects on the memory T cells at these sites. Secondly, by 
labeling OVA-specific T cells with tracking dyes, the spatial localization of Candida specific T 
cells relative to other immune cells and stromal cells of the oral mucosa and cLN can be assessed 
by imaging studies. Through this study, interactions of Candida specific T cells with their local 
environment and the potential distortions in the absence of IL-22 can be captured. Moreover, using 
pALS bearing MHC II tetramers, C. albicans specific responses can be characterized ex vivo. This 
study can be complemented with the use of pALS-specific TCR transgenic mice to further analyze 
the CD4 mediated memory response to C. albicans. 
Despite the dominant role of IL-17/IL-17RA signaling, this study suggests that effective 
oral antifungal immunity involves multiple coordinated signals, and thus the optimal outcomes 
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may derive from the integration of multiple cues. In the stratified oral mucosa, the differential 
localization of IL-22RA1 and IL-17RA is important for this coordinated response. The implication 
of this pattern of receptor localization in other oral pathologies (such as oral mucositis and oral 
squamous carcinomas) and intrinsic relationships between the cells in these niches is yet to be fully 
appreciated. The role of IL-22RA1 in the BEL to support IL-17RA expression in the SEL bolsters 
the requirement for the integration of signals from these disparate receptors signaling pathways. 
At the transcriptional level, the coordinated induction of STATs, CEBPs, I F and AP1 
transcription factors is likely to dictate optimal induction of key target genes and post-
transcriptional modifications in OPC. While data is available for STAT3 and C/EBPs, the direct 
functional roles of I F and AP1 are yet to be demonstrated.  
In this study, our observations were made by sublingual inoculation with a fixed dose of 
C. albicans. It is likely that altering the dose of the inoculum can influence the outcome of 
responses. The spectrum of epithelial-Candida responses is dependent on the density of hyphae.  
Invading hyphae cause epithelial damage which is part of the mechanism to discriminate between 
the transition from commensalism to virulence. Thus, the extent of damage dictates the ensuing 
host response. A previous in vitro study demonstrated that epithelial cells recognize C. albicans in 
a two-stage process which is determined by density and morphology of C. albicans [84]. The early 
response results in prolonged activation of NF-B and a transient activation of MAPK signaling. 
At the later stage which corresponds to higher hyphal density, there is a second wave of prolonged 
MAPK signaling [84]. Thus, the threshold of hyphal burden can activate different pathways to lead 
to the induction of different genes and possibly trigger varied effector responses. While the concept 
of the threshold effect of invading hyphae on the oral mucosa has not been explored in vivo, it can 
potentially alter the outcomes of anti-Candida immune responses and may be worth exploring. 
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This can be done by infecting with different doses of Candida and followed by assessment of 
fungal burdens and thorough characterization of epithelial and immune responses. 
6.3 Concluding Remarks 
The findings from this dissertation have provided insights into the molecular mechanisms 
underlying IL-22/IL-22RA1-mediated signaling in acute and T cell recall OPC settings. The search 
for effective anti-fungal vaccine is still ongoing, with considerations for different immunogenic 
proteins and vaccination strategies. Vaccine efficacy is heavily dependent on the identification of 
immune correlates of protection. Our current data support previous findings in the field that 
suggest that in addition to IFN- and IL-17A meditated T cell responses, an effective oral 
antifungal vaccine must also elicit IL-22 responses [74, 107, 196, 230]. Since anti-IL-17A 
antibodies are used in the clinic for treatment of IL-17A-mediated proinflammatory conditions, 
particularly psoriasis [121, 224, 354, 355], our data suggest that co-administration of anti-IL-22 
antibodies has potential to enhance susceptibility to fungal infections. Our T cell recall OPC data 
suggest the need for adoption of models that most closely reflect the observations in human OPC. 
While the acute OPC model has been instrumental in understanding and predicting the roles of 
innate IL-17RA responses in humans, recall infection models may provide further understanding, 
since OPC in humans is characterized by prolonged C. albicans antigen exposure. Thus, despite 
the advances made, some facets of oral antifungal immunity and oral mucosal immunity in general 
remain to be discovered. 
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